Aqvesme

Overview

mitapivat

pyruvate kinase inhibitor

• CYP3A4 substrate
• P-gp inhibitor, weak
• CYP2B6 inducer, weak
• CYP2C8 inducer, weak
• CYP2C9 inducer, weak
• CYP2C19 inducer, weak
• CYP3A4 inducer, moderate
• UGT1A1 inducer

Contraindicated

• colchicine
Aqvesme (mitapivat)

+

colchicine

1 interaction

Contraindicated

mitapivat + colchicine

CV RISK REDUCTION: consider monitoring CK, myopathy s/sx; GOUT OR FMF: contraindicated in pts w/ renal or hepatic impairment; otherwise, consider decr. colchicine dose during and x14 days after mitapivat use: combo may incr. or decr. colchicine levels, incr. risk of myopathy, rhabdomyolysis, other life-threatening toxicity or decr. efficacy (P-gp-mediated transport possibly inhibited, hepatic metabolism induced)

• lonafarnib
Aqvesme (mitapivat)

+

lonafarnib

1 interaction

Contraindicated

mitapivat + lonafarnib

contraindicated: combo may incr. mitapivat levels, risk of adverse effects; may decr. lonafarnib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• mavacamten
Aqvesme (mitapivat)

+

mavacamten

1 interaction

Contraindicated

mitapivat + mavacamten

contraindicated: combo may decr. levels, efficacy of both drugs (hepatic metabolism induced)

• ranolazine
Aqvesme (mitapivat)

+

ranolazine

1 interaction

Contraindicated

mitapivat + ranolazine

contraindicated: combo may incr. or decr. ranolazine levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism induced, P-gp-mediated transport possibly inhibited)

• zoliflodacin
Aqvesme (mitapivat)

+

zoliflodacin

1 interaction

Contraindicated

mitapivat + zoliflodacin

contraindicated: combo may decr. zoliflodacin levels, efficacy (hepatic metabolism induced)

Avoid/Use Alternative

• abemaciclib
Aqvesme (mitapivat)

+

abemaciclib

1 interaction

Avoid/Use Alternative

mitapivat + abemaciclib

avoid combo: combo may decr. abemaciclib levels, efficacy (hepatic metabolism induced)

• acoramidis
Aqvesme (mitapivat)

+

acoramidis

1 interaction

Avoid/Use Alternative

mitapivat + acoramidis

avoid combo: combo may decr. acoramidis levels, efficacy (UGT possibly induced)

• adagrasib
Aqvesme (mitapivat)

+

adagrasib

1 interaction

Avoid/Use Alternative

mitapivat + adagrasib

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. adagrasib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• alfentanil
Aqvesme (mitapivat)

+

alfentanil

1 interaction

Avoid/Use Alternative

mitapivat + alfentanil

use alternative or consider alfentanil dose adjustment: combo may decr. alfentanil levels, efficacy (hepatic metabolism induced)

• alpelisib
Aqvesme (mitapivat)

+

alpelisib

1 interaction

Avoid/Use Alternative

mitapivat + alpelisib

consider alternative: combo may decr. alpelisib levels, efficacy (hepatic metabolism induced)

• apalutamide
Aqvesme (mitapivat)

+

apalutamide

1 interaction

Avoid/Use Alternative

mitapivat + apalutamide

avoid combo: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• aprepitant
Aqvesme (mitapivat)

+

aprepitant

1 interaction

Avoid/Use Alternative

mitapivat + aprepitant

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. aprepitant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• artemether/lumefantrine
Aqvesme (mitapivat)

+

artemether/ lumefantrine

1 interaction

Avoid/Use Alternative

mitapivat + artemether/ lumefantrine

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• atazanavir
Aqvesme (mitapivat)

+

atazanavir

1 interaction

Avoid/Use Alternative

mitapivat + atazanavir

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. atazanavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• atogepant
Aqvesme (mitapivat)

+

atogepant

1 interaction

Avoid/Use Alternative

mitapivat + atogepant

CHRONIC MIGRAINE: avoid combo; EPISODIC MIGRAINE: incr. atogepant dose to 60 mg/day: combo may decr. atogepant levels, efficacy (hepatic metabolism induced)

• atrasentan
Aqvesme (mitapivat)

+

atrasentan

1 interaction

Avoid/Use Alternative

mitapivat + atrasentan

avoid combo: combo may decr. atrasentan levels, efficacy (hepatic metabolism induced)

• avacopan
Aqvesme (mitapivat)

+

avacopan

1 interaction

Avoid/Use Alternative

mitapivat + avacopan

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• avapritinib
Aqvesme (mitapivat)

+

avapritinib

1 interaction

Avoid/Use Alternative

mitapivat + avapritinib

avoid combo: combo may decr. avapritinib levels, efficacy (hepatic metabolism induced)

• axitinib
Aqvesme (mitapivat)

+

axitinib

1 interaction

Avoid/Use Alternative

mitapivat + axitinib

avoid combo: combo may decr. axitinib levels, efficacy (hepatic metabolism induced)

• bedaquiline
Aqvesme (mitapivat)

+

bedaquiline

1 interaction

Avoid/Use Alternative

mitapivat + bedaquiline

avoid combo: combo may decr. bedaquiline levels, efficacy (hepatic metabolism induced)

• berotralstat
Aqvesme (mitapivat)

+

berotralstat

1 interaction

Avoid/Use Alternative

mitapivat + berotralstat

THALASSEMIA: avoid combo; HEMOLYTIC ANEMIA: monitor Hgb; adjust max mitapivat dose to 20 mg bid: combo may incr. mitapivat levels, risk of adverse effects (hepatic metabolism inhibited)

• bictegravir
Aqvesme (mitapivat)

+

bictegravir

1 interaction

Avoid/Use Alternative

mitapivat + bictegravir

use alternative: combo may decr. bictegravir levels, efficacy (hepatic metabolism induced, UGT possibly induced)

• bosentan
Aqvesme (mitapivat)

+

bosentan

1 interaction

Avoid/Use Alternative

mitapivat + bosentan

consider alternative; otherwise, monitor Hgb and consider mitapivat dose adjustment up to max 100 mg bid: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• bosutinib
Aqvesme (mitapivat)

+

bosutinib

1 interaction

Avoid/Use Alternative

mitapivat + bosutinib

avoid combo: combo may decr. bosutinib levels, efficacy (hepatic metabolism induced)

• brigatinib
Aqvesme (mitapivat)

+

brigatinib

1 interaction

Avoid/Use Alternative

mitapivat + brigatinib

use alternative or monitor Hgb and incr. brigatinib daily dose after 7 days of concomitant tx; incr. by 30 mg increments q7 days as tolerated up to 2x maintenance dose: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• buprenorphine
Aqvesme (mitapivat)

+

buprenorphine

1 interaction

Avoid/Use Alternative

mitapivat + buprenorphine

use alternative or monitor withdrawal sx: combo may decr. buprenorphine levels, efficacy (hepatic metabolism induced)

• buspirone
Aqvesme (mitapivat)

+

buspirone

1 interaction

Avoid/Use Alternative

mitapivat + buspirone

consider alternative or adjust buspirone dose: combo may decr. buspirone levels, efficacy (hepatic metabolism induced)

• butalbital
Aqvesme (mitapivat)

+

butalbital

1 interaction

Avoid/Use Alternative

mitapivat + butalbital

avoid combo: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• cabotegravir
Aqvesme (mitapivat)

+

cabotegravir

1 interaction

Avoid/Use Alternative

mitapivat + cabotegravir

consider alternative: combo may decr. cabotegravir levels, efficacy (UGT possibly induced)

• cabozantinib
Aqvesme (mitapivat)

+

cabozantinib

1 interaction

Avoid/Use Alternative

mitapivat + cabozantinib

use alternative or incr. cabozantinib daily dose by 20 mg if renal cell CA, hepatocellular CA, differentiated thyroid CA, or NET use; consider cabozantinib dose adjustment if medullary thyroid CA use: combo may decr. cabozantinib levels, efficacy (hepatic metabolism induced)

• capivasertib
Aqvesme (mitapivat)

+

capivasertib

1 interaction

Avoid/Use Alternative

mitapivat + capivasertib

avoid combo: combo may decr. capivasertib levels, efficacy (hepatic metabolism induced)

• capmatinib
Aqvesme (mitapivat)

+

capmatinib

1 interaction

Avoid/Use Alternative

mitapivat + capmatinib

avoid combo: combo may decr. capmatinib levels, efficacy (hepatic metabolism induced)

• carbamazepine
Aqvesme (mitapivat)

+

carbamazepine

1 interaction

Avoid/Use Alternative

mitapivat + carbamazepine

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• cariprazine
Aqvesme (mitapivat)

+

cariprazine

1 interaction

Avoid/Use Alternative

mitapivat + cariprazine

avoid combo: combo may decr. cariprazine and active metabolite levels, efficacy (hepatic metabolism induced)

• cenobamate
Aqvesme (mitapivat)

+

cenobamate

1 interaction

Avoid/Use Alternative

mitapivat + cenobamate

consider alternative; otherwise, monitor Hgb and consider mitapivat dose adjustment up to max 100 mg bid: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• ceritinib
Aqvesme (mitapivat)

+

ceritinib

1 interaction

Avoid/Use Alternative

mitapivat + ceritinib

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. ceritinib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• chloramphenicol
Aqvesme (mitapivat)

+

chloramphenicol

1 interaction

Avoid/Use Alternative

mitapivat + chloramphenicol

avoid combo: combo may incr. mitapivat levels, risk of adverse effects (hepatic metabolism inhibited)

• ciprofloxacin
Aqvesme (mitapivat)

+

ciprofloxacin

1 interaction

Avoid/Use Alternative

mitapivat + ciprofloxacin

THALASSEMIA: avoid combo; HEMOLYTIC ANEMIA: monitor Hgb; adjust max mitapivat dose to 20 mg bid: combo may incr. mitapivat levels, risk of adverse effects (hepatic metabolism inhibited)

• clarithromycin
Aqvesme (mitapivat)

+

clarithromycin

1 interaction

Avoid/Use Alternative

mitapivat + clarithromycin

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. clarithromycin levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• clofazimine
Aqvesme (mitapivat)

+

clofazimine

1 interaction

Avoid/Use Alternative

mitapivat + clofazimine

THALASSEMIA: avoid combo; HEMOLYTIC ANEMIA: monitor Hgb; adjust max mitapivat dose to 20 mg bid: combo may incr. mitapivat levels, risk of adverse effects (hepatic metabolism inhibited)

• cobicistat
Aqvesme (mitapivat)

+

cobicistat

1 interaction

Avoid/Use Alternative

mitapivat + cobicistat

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. cobicistat levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• cobimetinib
Aqvesme (mitapivat)

+

cobimetinib

1 interaction

Avoid/Use Alternative

mitapivat + cobimetinib

avoid combo: combo may decr. cobimetinib levels, efficacy (hepatic metabolism induced)

• codeine
Aqvesme (mitapivat)

+

codeine

1 interaction

Avoid/Use Alternative

mitapivat + codeine

use alternative or monitor withdrawal sx: combo may decr. codeine and active metabolite morphine levels, efficacy (hepatic metabolism induced, may decr. production of active metabolite morphine)

• conivaptan
Aqvesme (mitapivat)

+

conivaptan

1 interaction

Avoid/Use Alternative

mitapivat + conivaptan

THALASSEMIA: avoid combo during and x7 days after conivaptan tx; HEMOLYTIC ANEMIA: monitor Hgb; adjust max mitapivat dose to 20 mg bid during and x7 days after conivaptan tx: combo may incr. mitapivat levels, risk of adverse effects (hepatic metabolism inhibited)

• crizotinib
Aqvesme (mitapivat)

+

crizotinib

1 interaction

Avoid/Use Alternative

mitapivat + crizotinib

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. crizotinib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• cyclosporine
Aqvesme (mitapivat)

+

cyclosporine

1 interaction

Avoid/Use Alternative

mitapivat + cyclosporine

THALASSEMIA: avoid combo; HEMOLYTIC ANEMIA: monitor Hgb, cyclosporine levels, renal fxn; adjust max mitapivat dose to 20 mg bid: combo may incr. mitapivat levels, risk of adverse effects; may incr. or decr. cyclosporine levels, incr. risk of nephrotoxicity, serious infection, other adverse effects or decr. efficacy (hepatic metabolism inhibited; P-gp-mediated transport possibly inhibited, hepatic metabolism induced)

• dabigatran
Aqvesme (mitapivat)

+

dabigatran

1 interaction

Avoid/Use Alternative

mitapivat + dabigatran

ATRIAL FIBRILLATION: avoid combo if CrCl <30 mL/min; OTHER INDICATIONS: avoid combo if CrCl <50 mL/min; if dabigatran use for DVT/PE prophylaxis post-hip replacement and CrCl >50 mL/min, consider separating admin. at least 2h apart: combo may incr. dabigatran levels, risk of bleeding (including life-threatening), other adverse effects (P-gp-mediated transport possibly inhibited)

• dabrafenib
Aqvesme (mitapivat)

+

dabrafenib

1 interaction

Avoid/Use Alternative

mitapivat + dabrafenib

consider alternative; otherwise, monitor Hgb and consider mitapivat dose adjustment up to max 100 mg bid: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• danazol
Aqvesme (mitapivat)

+

danazol

1 interaction

Avoid/Use Alternative

mitapivat + danazol

THALASSEMIA: avoid combo; HEMOLYTIC ANEMIA: monitor Hgb; adjust max mitapivat dose to 20 mg bid: combo may incr. mitapivat levels, risk of adverse effects (hepatic metabolism inhibited)

• daridorexant
Aqvesme (mitapivat)

+

daridorexant

1 interaction

Avoid/Use Alternative

mitapivat + daridorexant

avoid combo: combo may decr. daridorexant levels, efficacy (hepatic metabolism induced)

• darolutamide
Aqvesme (mitapivat)

+

darolutamide

1 interaction

Avoid/Use Alternative

mitapivat + darolutamide

avoid combo if also combined w/ P-gp inducer; otherwise, monitor Hgb: combo may incr. or decr. darolutamide levels, incr. risk of adverse effects or decr. efficacy; may decr. mitapivat levels, efficacy (hepatic metabolism induced, P-gp-mediated transport possibly inhibited; hepatic metabolism induced)

• darunavir
Aqvesme (mitapivat)

+

darunavir

1 interaction

Avoid/Use Alternative

mitapivat + darunavir

THALASSEMIA: avoid combo; HEMOLYTIC ANEMIA: monitor Hgb; adjust max mitapivat dose to 20 mg bid: combo may incr. mitapivat levels, risk of adverse effects; may decr. darunavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• defactinib
Aqvesme (mitapivat)

+

defactinib

1 interaction

Avoid/Use Alternative

mitapivat + defactinib

avoid combo: combo may decr. defactinib levels, efficacy (hepatic metabolism induced)

• deflazacort
Aqvesme (mitapivat)

+

deflazacort

1 interaction

Avoid/Use Alternative

mitapivat + deflazacort

avoid combo: combo may decr. deflazacort active metabolite levels, efficacy (hepatic metabolism induced)

• desogestrel (contraceptive)
Aqvesme (mitapivat)

+

desogestrel (contraceptive)

1 interaction

Avoid/Use Alternative

mitapivat + desogestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after mitapivat tx: combo may decr. desogestrel levels, contraceptive efficacy (hepatic metabolism induced)

• diazoxide
Aqvesme (mitapivat)

+

diazoxide

1 interaction

Avoid/Use Alternative

mitapivat + diazoxide

avoid combo if also combined w/ moderate or strong CYP1A2 inducer; otherwise, caution advised: combo may decr. diazoxide levels, efficacy (hepatic metabolism induced)

• dienogest (contraceptive)
Aqvesme (mitapivat)

+

dienogest (contraceptive)

1 interaction

Avoid/Use Alternative

mitapivat + dienogest (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after mitapivat tx: combo may decr. dienogest levels, contraceptive efficacy (hepatic metabolism induced)

• dihydrocodeine
Aqvesme (mitapivat)

+

dihydrocodeine

1 interaction

Avoid/Use Alternative

mitapivat + dihydrocodeine

use alternative or monitor withdrawal sx: combo may decr. dihydrocodeine and active metabolite dihydromorphine levels, efficacy (hepatic metabolism induced, may decr. production of active metabolite dihydromorphine)

• diltiazem
Aqvesme (mitapivat)

+

diltiazem

1 interaction

Avoid/Use Alternative

mitapivat + diltiazem

THALASSEMIA: avoid combo; HEMOLYTIC ANEMIA: use alternative or monitor Hgb; adjust max mitapivat dose to 20 mg bid: combo may incr. mitapivat levels, risk of adverse effects; may decr. diltiazem levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• dolutegravir
Aqvesme (mitapivat)

+

dolutegravir

1 interaction

Avoid/Use Alternative

mitapivat + dolutegravir

avoid combo: combo may decr. dolutegravir levels, efficacy (hepatic metabolism induced, UGT possibly induced)

• doravirine
Aqvesme (mitapivat)

+

doravirine

1 interaction

Avoid/Use Alternative

mitapivat + doravirine

avoid combo: combo may decr. doravirine levels, efficacy (hepatic metabolism induced)

• dordaviprone
Aqvesme (mitapivat)

+

dordaviprone

1 interaction

Avoid/Use Alternative

mitapivat + dordaviprone

avoid combo: combo may decr. dordaviprone levels, efficacy (hepatic metabolism induced)

• doxorubicin
Aqvesme (mitapivat)

+

doxorubicin

1 interaction

Avoid/Use Alternative

mitapivat + doxorubicin

avoid combo: combo may decr. doxorubicin levels, efficacy (hepatic metabolism induced)

• dronedarone
Aqvesme (mitapivat)

+

dronedarone

1 interaction

Avoid/Use Alternative

mitapivat + dronedarone

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. dronedarone levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• drospirenone (contraceptive)
Aqvesme (mitapivat)

+

drospirenone (contraceptive)

1 interaction

Avoid/Use Alternative

mitapivat + drospirenone (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after mitapivat tx: combo may decr. drospirenone levels, contraceptive efficacy (hepatic metabolism induced)

• duvelisib
Aqvesme (mitapivat)

+

duvelisib

1 interaction

Avoid/Use Alternative

mitapivat + duvelisib

THALASSEMIA: avoid combo; HEMOLYTIC ANEMIA: use alternative or monitor Hgb, adjust max mitapivat dose to 20 mg bid and incr. duvelisib dose on day 12 of mitapivat tx as follows: if on duvelisib 25 mg bid, incr. to 40 mg bid; if on duvelisib 15 mg bid, incr. to 25 mg bid: combo may incr. mitapivat levels, risk of adverse effects; may decr. duvelisib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• efavirenz
Aqvesme (mitapivat)

+

efavirenz

1 interaction

Avoid/Use Alternative

mitapivat + efavirenz

consider alternative; otherwise, monitor Hgb and consider mitapivat dose adjustment up to max 100 mg bid: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• elacestrant
Aqvesme (mitapivat)

+

elacestrant

1 interaction

Avoid/Use Alternative

mitapivat + elacestrant

avoid combo: combo may decr. elacestrant levels, efficacy (hepatic metabolism induced)

• elagolix
Aqvesme (mitapivat)

+

elagolix

1 interaction

Avoid/Use Alternative

mitapivat + elagolix

if elagolix 300 mg bid regimen, consider alternative; otherwise, monitor Hgb and consider mitapivat dose adjustment up to max 100 mg bid; if elagolix 200 mg bid regimen or 150 mg qd regimen, monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• elbasvir
Aqvesme (mitapivat)

+

elbasvir

1 interaction

Avoid/Use Alternative

mitapivat + elbasvir

avoid combo: combo may decr. elbasvir levels, efficacy (hepatic metabolism induced)

• elexacaftor/tezacaftor/ivacaftor
Aqvesme (mitapivat)

+

elexacaftor/ tezacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

mitapivat + elexacaftor/ tezacaftor/ ivacaftor

avoid combo: combo may decr. elexacaftor/tezacaftor/ivacaftor levels, efficacy (hepatic metabolism induced)

• elinzanetant
Aqvesme (mitapivat)

+

elinzanetant

1 interaction

Avoid/Use Alternative

mitapivat + elinzanetant

avoid combo: combo may decr. elinzanetant levels, efficacy (hepatic metabolism induced)

• elvitegravir
Aqvesme (mitapivat)

+

elvitegravir

1 interaction

Avoid/Use Alternative

mitapivat + elvitegravir

avoid combo: combo may decr. elvitegravir levels, efficacy (hepatic metabolism induced)

• encorafenib
Aqvesme (mitapivat)

+

encorafenib

1 interaction

Avoid/Use Alternative

mitapivat + encorafenib

avoid combo: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• ensartinib
Aqvesme (mitapivat)

+

ensartinib

1 interaction

Avoid/Use Alternative

mitapivat + ensartinib

avoid combo: combo may incr. or decr. ensartinib levels, incr. risk of bradycardia, hyperglycemia, other adverse effects or decr. efficacy (P-gp-mediated transport possibly inhibited, hepatic metabolism possibly induced)

• entrectinib
Aqvesme (mitapivat)

+

entrectinib

1 interaction

Avoid/Use Alternative

mitapivat + entrectinib

avoid combo: combo may decr. entrectinib levels, efficacy (hepatic metabolism induced)

• enzalutamide
Aqvesme (mitapivat)

+

enzalutamide

1 interaction

Avoid/Use Alternative

mitapivat + enzalutamide

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• erdafitinib
Aqvesme (mitapivat)

+

erdafitinib

1 interaction

Avoid/Use Alternative

mitapivat + erdafitinib

use alternative or initiate erdafitinib at 9 mg qd: combo may decr. erdafitinib levels, efficacy (hepatic metabolism induced)

• erlotinib
Aqvesme (mitapivat)

+

erlotinib

1 interaction

Avoid/Use Alternative

mitapivat + erlotinib

use alternative or incr. erlotinib dose by 50mg/day q2wk up to 450 mg/day: combo may decr. erlotinib levels, efficacy (hepatic metabolism induced)

• erythromycin
Aqvesme (mitapivat)

+

erythromycin

1 interaction

Avoid/Use Alternative

mitapivat + erythromycin

THALASSEMIA: avoid combo; HEMOLYTIC ANEMIA: monitor Hgb; adjust max mitapivat dose to 20 mg bid: combo may incr. mitapivat levels, risk of adverse effects; may decr. erythromycin levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• estradiol (contraceptive)
Aqvesme (mitapivat)

+

estradiol (contraceptive)

1 interaction

Avoid/Use Alternative

mitapivat + estradiol (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after mitapivat tx: combo may decr. estradiol levels, contraceptive efficacy (hepatic metabolism induced, UGT possibly induced)

• ethinyl estradiol (contraceptive)
Aqvesme (mitapivat)

+

ethinyl estradiol (contraceptive)

1 interaction

Avoid/Use Alternative

mitapivat + ethinyl estradiol (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after mitapivat tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metabolism induced, UGT possibly induced)

• ethynodiol (contraceptive)
Aqvesme (mitapivat)

+

ethynodiol (contraceptive)

1 interaction

Avoid/Use Alternative

mitapivat + ethynodiol (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after mitapivat tx: combo may decr. ethynodiol and active metabolite levels, contraceptive efficacy (hepatic metabolism induced)

• etonogestrel (contraceptive)
Aqvesme (mitapivat)

+

etonogestrel (contraceptive)

1 interaction

Avoid/Use Alternative

mitapivat + etonogestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after mitapivat tx: combo may decr. etonogestrel levels, contraceptive efficacy (hepatic metabolism induced)

• etravirine
Aqvesme (mitapivat)

+

etravirine

1 interaction

Avoid/Use Alternative

mitapivat + etravirine

consider alternative; otherwise, monitor Hgb and consider mitapivat dose adjustment up to max 100 mg bid: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• everolimus
Aqvesme (mitapivat)

+

everolimus

1 interaction

Avoid/Use Alternative

mitapivat + everolimus

consider alternative: combo may incr. or decr. everolimus levels, incr. risk of serious infection, myelosuppression, other adverse effects or decr. efficacy (hepatic metabolism induced, P-gp-mediated transport possibly inhibited)

• fedratinib
Aqvesme (mitapivat)

+

fedratinib

1 interaction

Avoid/Use Alternative

mitapivat + fedratinib

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. fedratinib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• felodipine
Aqvesme (mitapivat)

+

felodipine

1 interaction

Avoid/Use Alternative

mitapivat + felodipine

use alternative: combo may decr. felodipine levels, efficacy (hepatic metabolism induced)

• fentanyl
Aqvesme (mitapivat)

+

fentanyl

1 interaction

Avoid/Use Alternative

mitapivat + fentanyl

use alternative or monitor withdrawal sx: combo may decr. fentanyl levels, efficacy (hepatic metabolism induced)

• fexinidazole
Aqvesme (mitapivat)

+

fexinidazole

1 interaction

Avoid/Use Alternative

mitapivat + fexinidazole

consider alternative; otherwise, monitor ECG, Hgb and consider mitapivat dose adjustment up to max 100 mg bid: combo may incr. fexinidazole active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. mitapivat levels, efficacy (hepatic metabolism induced, incr. conversion to active metabolites)

• finerenone
Aqvesme (mitapivat)

+

finerenone

1 interaction

Avoid/Use Alternative

mitapivat + finerenone

avoid combo: combo may decr. finerenone levels, efficacy (hepatic metabolism induced)

• fluconazole
Aqvesme (mitapivat)

+

fluconazole

1 interaction

Avoid/Use Alternative

mitapivat + fluconazole

THALASSEMIA: avoid combo; HEMOLYTIC ANEMIA: monitor Hgb; adjust max mitapivat dose to 20 mg bid: combo may incr. mitapivat levels, risk of adverse effects (hepatic metabolism inhibited)

• fosamprenavir
Aqvesme (mitapivat)

+

fosamprenavir

1 interaction

Avoid/Use Alternative

mitapivat + fosamprenavir

avoid combo: combo may incr. or decr. mitapivat levels, incr. risk of adverse effects or decr. efficacy; may decr. amprenavir levels, efficacy (hepatic metabolism altered; hepatic metabolism induced)

• fosaprepitant
Aqvesme (mitapivat)

+

fosaprepitant

1 interaction

Avoid/Use Alternative

mitapivat + fosaprepitant

avoid combo: combo may decr. aprepitant levels, efficacy (hepatic metabolism induced)

• fosphenytoin
Aqvesme (mitapivat)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

mitapivat + fosphenytoin

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• fostamatinib
Aqvesme (mitapivat)

+

fostamatinib

1 interaction

Avoid/Use Alternative

mitapivat + fostamatinib

use alternative: combo may decr. fostamatinib active metabolite levels, efficacy (hepatic metabolism induced)

• fruquintinib
Aqvesme (mitapivat)

+

fruquintinib

1 interaction

Avoid/Use Alternative

mitapivat + fruquintinib

use alternative: combo may decr. fruquintinib levels, efficacy (hepatic metabolism induced)

• ganaxolone
Aqvesme (mitapivat)

+

ganaxolone

1 interaction

Avoid/Use Alternative

mitapivat + ganaxolone

use alternative or consider ganaxolone dose adjustment: combo may decr. ganaxolone levels, efficacy (hepatic metabolism induced)

• gepotidacin
Aqvesme (mitapivat)

+

gepotidacin

1 interaction

Avoid/Use Alternative

mitapivat + gepotidacin

UROGENITAL GONORRHEA: avoid combo; URINARY TRACT INFECTION: caution advised: combo may decr. gepotidacin levels, efficacy (hepatic metabolism induced)

• gilteritinib
Aqvesme (mitapivat)

+

gilteritinib

1 interaction

Avoid/Use Alternative

mitapivat + gilteritinib

avoid combo if also combined w/ P-gp inducer; otherwise, consider alternative: combo may decr. gilteritinib levels, efficacy (hepatic metabolism induced)

• glasdegib
Aqvesme (mitapivat)

+

glasdegib

1 interaction

Avoid/Use Alternative

mitapivat + glasdegib

use alternative or incr. glasdegib dose as follows: if on glasdegib 100 mg qd, incr. to 200 mg qd; if on glasdegib 50 mg qd, incr. to 100 mg qd: combo may decr. glasdegib levels, efficacy (hepatic metabolism induced)

• glecaprevir
Aqvesme (mitapivat)

+

glecaprevir

1 interaction

Avoid/Use Alternative

mitapivat + glecaprevir

avoid combo: combo may incr. or decr. glecaprevir levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport possibly inhibited, hepatic metabolism induced)

• grapefruit
Aqvesme (mitapivat)

+

grapefruit

1 interaction

Avoid/Use Alternative

mitapivat + grapefruit

avoid grapefruit juice: combo may incr. mitapivat levels, risk of adverse effects (GI metabolism inhibited)

• grazoprevir
Aqvesme (mitapivat)

+

grazoprevir

1 interaction

Avoid/Use Alternative

mitapivat + grazoprevir

avoid combo: combo may decr. grazoprevir levels, efficacy (hepatic metabolism induced)

• hydrocodone
Aqvesme (mitapivat)

+

hydrocodone

1 interaction

Avoid/Use Alternative

mitapivat + hydrocodone

use alternative or monitor withdrawal sx: combo may decr. hydrocodone levels, efficacy (hepatic metabolism induced)

• ibrexafungerp
Aqvesme (mitapivat)

+

ibrexafungerp

1 interaction

Avoid/Use Alternative

mitapivat + ibrexafungerp

avoid combo: combo may decr. ibrexafungerp levels, efficacy (hepatic metabolism induced)

• ibrutinib
Aqvesme (mitapivat)

+

ibrutinib

1 interaction

Avoid/Use Alternative

mitapivat + ibrutinib

avoid combo: combo may decr. ibrutinib levels, efficacy (hepatic metabolism induced)

• idelalisib
Aqvesme (mitapivat)

+

idelalisib

1 interaction

Avoid/Use Alternative

mitapivat + idelalisib

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. idelalisib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• imatinib
Aqvesme (mitapivat)

+

imatinib

1 interaction

Avoid/Use Alternative

mitapivat + imatinib

THALASSEMIA: avoid combo; HEMOLYTIC ANEMIA: use alternative or monitor Hgb; adjust max mitapivat dose to 20 mg bid; consider imatinib dose adjustment: combo may incr. mitapivat levels, risk of adverse effects; may decr. imatinib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• irinotecan
Aqvesme (mitapivat)

+

irinotecan

1 interaction

Avoid/Use Alternative

mitapivat + irinotecan

use alternative or D/C mitapivat >2wk prior to irinotecan start: combo may decr. irinotecan and active metabolite levels, efficacy (hepatic metabolism induced)

• isavuconazonium
Aqvesme (mitapivat)

+

isavuconazonium

1 interaction

Avoid/Use Alternative

mitapivat + isavuconazonium

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. isavuconazole levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• isradipine
Aqvesme (mitapivat)

+

isradipine

1 interaction

Avoid/Use Alternative

mitapivat + isradipine

consider alternative: combo may decr. isradipine levels, efficacy (hepatic metabolism induced)

• istradefylline
Aqvesme (mitapivat)

+

istradefylline

1 interaction

Avoid/Use Alternative

mitapivat + istradefylline

avoid combo: combo may decr. istradefylline levels, efficacy (hepatic metabolism induced)

• itraconazole
Aqvesme (mitapivat)

+

itraconazole

1 interaction

Avoid/Use Alternative

mitapivat + itraconazole

avoid combo 2wk before, during, and x2wk after itraconazole tx: combo may incr. mitapivat levels, risk of adverse effects; may decr. itraconazole levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• ivacaftor
Aqvesme (mitapivat)

+

ivacaftor

1 interaction

Avoid/Use Alternative

mitapivat + ivacaftor

avoid combo: combo may decr. ivacaftor levels, efficacy (hepatic metabolism induced)

• ivosidenib
Aqvesme (mitapivat)

+

ivosidenib

1 interaction

Avoid/Use Alternative

mitapivat + ivosidenib

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• ketoconazole
Aqvesme (mitapivat)

+

ketoconazole

1 interaction

Avoid/Use Alternative

mitapivat + ketoconazole

avoid combo 2wk before, during, and up to 1wk after ketoconazole tx: combo may incr. mitapivat levels, risk of adverse effects; may decr. ketoconazole levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• larotrectinib
Aqvesme (mitapivat)

+

larotrectinib

1 interaction

Avoid/Use Alternative

mitapivat + larotrectinib

use alternative or double larotrectinib dose: combo may decr. larotrectinib levels, efficacy (hepatic metabolism induced)

• lazertinib
Aqvesme (mitapivat)

+

lazertinib

1 interaction

Avoid/Use Alternative

mitapivat + lazertinib

avoid combo: combo may decr. lazertinib levels, efficacy (hepatic metabolism induced)

• lefamulin
Aqvesme (mitapivat)

+

lefamulin

1 interaction

Avoid/Use Alternative

mitapivat + lefamulin

THALASSEMIA: avoid combo with oral lefamulin; use alternative with IV lefamulin; HEMOLYTIC ANEMIA: use alternative: combo may decr. oral or IV lefamulin levels, efficacy; combo with oral lefamulin may incr. mitapivat levels, risk of adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

• lemborexant
Aqvesme (mitapivat)

+

lemborexant

1 interaction

Avoid/Use Alternative

mitapivat + lemborexant

avoid combo: combo may decr. lemborexant levels, efficacy (hepatic metabolism induced)

• lenacapavir
Aqvesme (mitapivat)

+

lenacapavir

1 interaction

Avoid/Use Alternative

mitapivat + lenacapavir

THALASSEMIA: avoid combo during and x9mo after lenacapavir tx; HEMOLYTIC ANEMIA: monitor Hgb; adjust max mitapivat dose to 20 mg bid during and x9mo after lenacapavir tx; HIV INFECTION: avoid combo; HIV PRE-EXPOSURE PROPHYLAXIS: on day mitapivat is initiated, give supplemental lenacapavir 463.5 mg SC x1; if mitapivat use >6mo, give supplemental lenacapavir 463.5 mg SC x1 every 6mo from mitapivat initiation; consider alternative if already receiving mitapivat, dosing regimen not established: combo may decr. lenacapavir levels, efficacy; may incr. mitapivat levels, risk of adverse effects (hepatic metabolism induced, UGT possibly induced; hepatic metabolism inhibited)

• leniolisib
Aqvesme (mitapivat)

+

leniolisib

1 interaction

Avoid/Use Alternative

mitapivat + leniolisib

avoid combo: combo may decr. leniolisib levels, efficacy (hepatic metabolism induced)

• letermovir
Aqvesme (mitapivat)

+

letermovir

1 interaction

Avoid/Use Alternative

mitapivat + letermovir

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. letermovir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced, UGT possibly induced)

• levoketoconazole
Aqvesme (mitapivat)

+

levoketoconazole

1 interaction

Avoid/Use Alternative

mitapivat + levoketoconazole

avoid combo x2wk before and during levoketoconazole tx: combo may incr. mitapivat levels, risk of adverse effects; may decr. levoketoconazole levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• levonorgestrel (contraceptive)
Aqvesme (mitapivat)

+

levonorgestrel (contraceptive)

1 interaction

Avoid/Use Alternative

mitapivat + levonorgestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after mitapivat tx: combo may decr. levonorgestrel levels, contraceptive efficacy (hepatic metabolism induced)

• levonorgestrel (post-coital contraceptive)
Aqvesme (mitapivat)

+

levonorgestrel (post-coital contraceptive)

1 interaction

Avoid/Use Alternative

mitapivat + levonorgestrel (post-coital contraceptive)

consider alternative: combo may decr. levonorgestrel levels, post-coital contraceptive efficacy (hepatic metabolism induced)

• lopinavir/ritonavir
Aqvesme (mitapivat)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

mitapivat + lopinavir/ ritonavir

avoid combo: combo may incr. or decr. mitapivat levels, incr. risk of adverse effects or decr. efficacy; may decr. lopinavir/ritonavir levels, efficacy (hepatic metabolism altered; hepatic metabolism induced)

• lorlatinib
Aqvesme (mitapivat)

+

lorlatinib

1 interaction

Avoid/Use Alternative

mitapivat + lorlatinib

use alternative or incr. lorlatinib dose to 125 mg qd, monitor Hgb and consider mitapivat dose adjustment up to max 100 mg bid: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• lumacaftor/ivacaftor
Aqvesme (mitapivat)

+

lumacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

mitapivat + lumacaftor/ ivacaftor

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• lumateperone
Aqvesme (mitapivat)

+

lumateperone

1 interaction

Avoid/Use Alternative

mitapivat + lumateperone

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metabolism induced)

• macitentan
Aqvesme (mitapivat)

+

macitentan

1 interaction

Avoid/Use Alternative

mitapivat + macitentan

avoid combo: combo may decr. macitentan levels, efficacy (hepatic metabolism induced)

• maraviroc
Aqvesme (mitapivat)

+

maraviroc

1 interaction

Avoid/Use Alternative

mitapivat + maraviroc

ADULTS: adjust maraviroc dose to 600 mg bid; if also combined w/ strong CYP3A4 inhibitor, adjust maraviroc dose to 150 mg bid; PEDS: avoid combo: combo may decr. maraviroc levels, efficacy (hepatic metabolism induced)

• medroxyprogesterone (contraceptive)
Aqvesme (mitapivat)

+

medroxyprogesterone (contraceptive)

1 interaction

Avoid/Use Alternative

mitapivat + medroxyprogesterone (contraceptive)

use additional non-hormonal or alternative contraception: combo may decr. medroxyprogesterone levels, contraceptive efficacy (hepatic metabolism induced)

• meperidine
Aqvesme (mitapivat)

+

meperidine

1 interaction

Avoid/Use Alternative

mitapivat + meperidine

use alternative or monitor withdrawal sx: combo may decr. meperidine levels, efficacy; may incr. normeperidine levels, risk of neurotoxicity (hepatic metabolism induced, incr. toxic metabolite formation)

• methadone
Aqvesme (mitapivat)

+

methadone

1 interaction

Avoid/Use Alternative

mitapivat + methadone

use alternative or monitor for withdrawal sx: combo may decr. methadone levels, efficacy (hepatic metabolism induced)

• midazolam
Aqvesme (mitapivat)

+

midazolam

1 interaction

Avoid/Use Alternative

mitapivat + midazolam

use alternative to oral midazolam; other midazolam routes OK: combo may decr. midazolam levels, efficacy (hepatic metabolism induced)

• midostaurin
Aqvesme (mitapivat)

+

midostaurin

1 interaction

Avoid/Use Alternative

mitapivat + midostaurin

consider alternative: combo may decr. midostaurin levels, efficacy (hepatic metabolism induced)

• mifepristone
Aqvesme (mitapivat)

+

mifepristone

1 interaction

Avoid/Use Alternative

mitapivat + mifepristone

avoid combo during and x14 days after daily mifepristone use; caution advised if pregnancy termination use: combo may incr. mitapivat levels, risk of adverse effects; may decr. mifepristone levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• mitotane
Aqvesme (mitapivat)

+

mitotane

1 interaction

Avoid/Use Alternative

mitapivat + mitotane

avoid combo: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• mobocertinib
Aqvesme (mitapivat)

+

mobocertinib

1 interaction

Avoid/Use Alternative

mitapivat + mobocertinib

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• modafinil
Aqvesme (mitapivat)

+

modafinil

1 interaction

Avoid/Use Alternative

mitapivat + modafinil

consider alternative; otherwise, monitor Hgb and consider mitapivat dose adjustment up to max 100 mg bid: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• nafcillin
Aqvesme (mitapivat)

+

nafcillin

1 interaction

Avoid/Use Alternative

mitapivat + nafcillin

consider alternative; otherwise, monitor Hgb and consider mitapivat dose adjustment up to max 100 mg bid: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• naldemedine
Aqvesme (mitapivat)

+

naldemedine

1 interaction

Avoid/Use Alternative

mitapivat + naldemedine

use alternative: combo may incr. or decr. naldemedine levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism induced, P-gp-mediated transport possibly inhibited)

• naloxegol
Aqvesme (mitapivat)

+

naloxegol

1 interaction

Avoid/Use Alternative

mitapivat + naloxegol

consider alternative: combo may decr. naloxegol levels, efficacy (hepatic metabolism induced)

• nefazodone
Aqvesme (mitapivat)

+

nefazodone

1 interaction

Avoid/Use Alternative

mitapivat + nefazodone

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. nefazodone levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• nelfinavir
Aqvesme (mitapivat)

+

nelfinavir

1 interaction

Avoid/Use Alternative

mitapivat + nelfinavir

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. nelfinavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• nerandomilast
Aqvesme (mitapivat)

+

nerandomilast

1 interaction

Avoid/Use Alternative

mitapivat + nerandomilast

avoid combo: combo may decr. nerandomilast levels, efficacy (hepatic metabolism possibly induced)

• neratinib
Aqvesme (mitapivat)

+

neratinib

1 interaction

Avoid/Use Alternative

mitapivat + neratinib

avoid combo: combo may incr. or decr. neratinib levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport possibly inhibited, hepatic metabolism induced)

• netupitant
Aqvesme (mitapivat)

+

netupitant

1 interaction

Avoid/Use Alternative

mitapivat + netupitant

THALASSEMIA: avoid combo; HEMOLYTIC ANEMIA: consider alternative: combo may incr. mitapivat levels, risk of adverse effects; may decr. netupitant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• nevirapine
Aqvesme (mitapivat)

+

nevirapine

1 interaction

Avoid/Use Alternative

mitapivat + nevirapine

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• nicardipine
Aqvesme (mitapivat)

+

nicardipine

1 interaction

Avoid/Use Alternative

mitapivat + nicardipine

use alternative or monitor BP: combo may decr. nicardipine levels, efficacy (hepatic metabolism induced)

• nifedipine
Aqvesme (mitapivat)

+

nifedipine

1 interaction

Avoid/Use Alternative

mitapivat + nifedipine

use alternative: combo may decr. nifedipine levels, efficacy (hepatic metabolism induced)

• nilotinib
Aqvesme (mitapivat)

+

nilotinib

1 interaction

Avoid/Use Alternative

mitapivat + nilotinib

THALASSEMIA: avoid combo; HEMOLYTIC ANEMIA: consider alternative or monitor Hgb; adjust max mitapivat dose to 20 mg bid: combo may incr. mitapivat levels, risk of adverse effects; may decr. nilotinib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• nirmatrelvir
Aqvesme (mitapivat)

+

nirmatrelvir

1 interaction

Avoid/Use Alternative

mitapivat + nirmatrelvir

avoid combo: combo may decr. nirmatrelvir levels, efficacy (hepatic metabolism induced)

• nirogacestat
Aqvesme (mitapivat)

+

nirogacestat

1 interaction

Avoid/Use Alternative

mitapivat + nirogacestat

avoid combo: combo may decr. nirogacestat levels, efficacy; may incr. mitapivat levels, risk of adverse effects (hepatic metabolism induced; hepatic metabolism inhibited)

• nisoldipine
Aqvesme (mitapivat)

+

nisoldipine

1 interaction

Avoid/Use Alternative

mitapivat + nisoldipine

use alternative or monitor BP: combo may decr. nisoldipine levels, efficacy (hepatic metabolism induced)

• norelgestromin (contraceptive)
Aqvesme (mitapivat)

+

norelgestromin (contraceptive)

1 interaction

Avoid/Use Alternative

mitapivat + norelgestromin (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after mitapivat tx: combo may decr. norelgestromin levels, contraceptive efficacy (hepatic metabolism induced)

• norethindrone (contraceptive)
Aqvesme (mitapivat)

+

norethindrone (contraceptive)

1 interaction

Avoid/Use Alternative

mitapivat + norethindrone (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after mitapivat tx: combo may decr. norethindrone levels, contraceptive efficacy (hepatic metabolism induced)

• norgestimate (contraceptive)
Aqvesme (mitapivat)

+

norgestimate (contraceptive)

1 interaction

Avoid/Use Alternative

mitapivat + norgestimate (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after mitapivat tx: combo may decr. norgestimate and active metabolites levels, contraceptive efficacy (hepatic metabolism induced)

• norgestrel (contraceptive)
Aqvesme (mitapivat)

+

norgestrel (contraceptive)

1 interaction

Avoid/Use Alternative

mitapivat + norgestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after mitapivat tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metabolism induced)

• olaparib
Aqvesme (mitapivat)

+

olaparib

1 interaction

Avoid/Use Alternative

mitapivat + olaparib

avoid combo: combo may decr. olaparib levels, efficacy (hepatic metabolism induced)

• oliceridine
Aqvesme (mitapivat)

+

oliceridine

1 interaction

Avoid/Use Alternative

mitapivat + oliceridine

use alternative or monitor withdrawal sx; consider oliceridine dose adjustment: combo may decr. oliceridine levels, efficacy (hepatic metabolism induced)

• olutasidenib
Aqvesme (mitapivat)

+

olutasidenib

1 interaction

Avoid/Use Alternative

mitapivat + olutasidenib

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• omaveloxolone
Aqvesme (mitapivat)

+

omaveloxolone

1 interaction

Avoid/Use Alternative

mitapivat + omaveloxolone

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• oxycodone
Aqvesme (mitapivat)

+

oxycodone

1 interaction

Avoid/Use Alternative

mitapivat + oxycodone

use alternative or monitor withdrawal sx: combo may decr. oxycodone levels, efficacy (hepatic metabolism induced)

• pacritinib
Aqvesme (mitapivat)

+

pacritinib

1 interaction

Avoid/Use Alternative

mitapivat + pacritinib

consider alternative; otherwise, monitor Hgb and consider mitapivat dose adjustment up to max 100 mg bid: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• palbociclib
Aqvesme (mitapivat)

+

palbociclib

1 interaction

Avoid/Use Alternative

mitapivat + palbociclib

avoid combo: combo may decr. palbociclib levels, efficacy (hepatic metabolism induced)

• palovarotene
Aqvesme (mitapivat)

+

palovarotene

1 interaction

Avoid/Use Alternative

mitapivat + palovarotene

avoid combo: combo may decr. palovarotene levels, efficacy (hepatic metabolism induced)

• pemigatinib
Aqvesme (mitapivat)

+

pemigatinib

1 interaction

Avoid/Use Alternative

mitapivat + pemigatinib

avoid combo: combo may decr. pemigatinib levels, efficacy (hepatic metabolism induced)

• pentobarbital
Aqvesme (mitapivat)

+

pentobarbital

1 interaction

Avoid/Use Alternative

mitapivat + pentobarbital

avoid combo: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• pexidartinib
Aqvesme (mitapivat)

+

pexidartinib

1 interaction

Avoid/Use Alternative

mitapivat + pexidartinib

consider alternative; otherwise, monitor Hgb and consider mitapivat dose adjustment up to max 100 mg bid: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• phenobarbital
Aqvesme (mitapivat)

+

phenobarbital

1 interaction

Avoid/Use Alternative

mitapivat + phenobarbital

avoid combo: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• phenytoin
Aqvesme (mitapivat)

+

phenytoin

1 interaction

Avoid/Use Alternative

mitapivat + phenytoin

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• pimavanserin
Aqvesme (mitapivat)

+

pimavanserin

1 interaction

Avoid/Use Alternative

mitapivat + pimavanserin

avoid combo: combo may decr. pimavanserin levels, efficacy (hepatic metabolism induced)

• pirtobrutinib
Aqvesme (mitapivat)

+

pirtobrutinib

1 interaction

Avoid/Use Alternative

mitapivat + pirtobrutinib

use alternative or incr. pirtobrutinib dose as follows: if on pirtobrutinib 200 mg qd, incr. to 300 mg; if on pirtobrutinib 100 mg qd, incr. to 150 mg; if on pirtobrutinib 50 mg qd, incr. to 100 mg: combo may decr. pirtobrutinib levels, efficacy (hepatic metabolism induced)

• ponatinib
Aqvesme (mitapivat)

+

ponatinib

1 interaction

Avoid/Use Alternative

mitapivat + ponatinib

use alternative: combo may decr. ponatinib levels, efficacy (hepatic metabolism induced)

• posaconazole
Aqvesme (mitapivat)

+

posaconazole

1 interaction

Avoid/Use Alternative

mitapivat + posaconazole

avoid combo: combo may incr. mitapivat levels, risk of adverse effects (hepatic metabolism inhibited)

• pralsetinib
Aqvesme (mitapivat)

+

pralsetinib

1 interaction

Avoid/Use Alternative

mitapivat + pralsetinib

consider alternative: combo may incr. or decr. pralsetinib levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (P-gp-mediated transport possibly inhibited, hepatic metabolism induced)

• praziquantel
Aqvesme (mitapivat)

+

praziquantel

1 interaction

Avoid/Use Alternative

mitapivat + praziquantel

use alternative or D/C mitapivat at least 2wk prior to praziquantel start; if immediate schistosomiasis tx required, monitor anthelmintic efficacy: combo may decr. praziquantel levels, efficacy (hepatic metabolism induced)

• pretomanid
Aqvesme (mitapivat)

+

pretomanid

1 interaction

Avoid/Use Alternative

mitapivat + pretomanid

avoid combo: combo may decr. pretomanid levels, efficacy (hepatic metabolism induced)

• primidone
Aqvesme (mitapivat)

+

primidone

1 interaction

Avoid/Use Alternative

mitapivat + primidone

avoid combo: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• quizartinib
Aqvesme (mitapivat)

+

quizartinib

1 interaction

Avoid/Use Alternative

mitapivat + quizartinib

avoid combo: combo may decr. quizartinib levels, efficacy (hepatic metabolism induced)

• relacorilant
Aqvesme (mitapivat)

+

relacorilant

1 interaction

Avoid/Use Alternative

mitapivat + relacorilant

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. relacorilant levels, efficacy (hepatic metabolism inhibited; hepatic metabolism possibly induced)

• relugolix
Aqvesme (mitapivat)

+

relugolix

1 interaction

Avoid/Use Alternative

mitapivat + relugolix

PROSTATE CANCER: may hold relugolix if mitapivat tx up to 2wk; otherwise, use alternative or monitor ECG, electrolytes and admin. relugolix at least 6h before mitapivat; FIBROID-ASSOC. BLEEDING: use alternative or admin. relugolix at least 6h before mitapivat: combo may incr. or decr. relugolix levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (gut P-gp-mediated transport possibly inhibited, hepatic metabolism induced)

• remibrutinib
Aqvesme (mitapivat)

+

remibrutinib

1 interaction

Avoid/Use Alternative

mitapivat + remibrutinib

avoid combo: combo may decr. remibrutinib levels, efficacy (hepatic metabolism induced)

• repotrectinib
Aqvesme (mitapivat)

+

repotrectinib

1 interaction

Avoid/Use Alternative

mitapivat + repotrectinib

avoid combo: combo may incr. or decr. repotrectinib levels, incr. risk of adverse effects or decr. efficacy; may decr mitapivat levels, efficacy (hepatic metabolism induced, P-gp-mediated transport inhibited; hepatic metabolism induced)

• revumenib
Aqvesme (mitapivat)

+

revumenib

1 interaction

Avoid/Use Alternative

mitapivat + revumenib

avoid combo: combo may decr. revumenib levels, efficacy; may incr. revumenib active metabolite levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism induced; incr. active metabolite formation)

• ribociclib
Aqvesme (mitapivat)

+

ribociclib

1 interaction

Avoid/Use Alternative

mitapivat + ribociclib

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. ribociclib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• rifabutin
Aqvesme (mitapivat)

+

rifabutin

1 interaction

Avoid/Use Alternative

mitapivat + rifabutin

avoid combo: combo may decr. levels, efficacy of both drugs (hepatic metabolism induced)

• rifampin
Aqvesme (mitapivat)

+

rifampin

1 interaction

Avoid/Use Alternative

mitapivat + rifampin

avoid combo: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• rifapentine
Aqvesme (mitapivat)

+

rifapentine

1 interaction

Avoid/Use Alternative

mitapivat + rifapentine

consider alternative; otherwise, monitor Hgb and consider mitapivat dose adjustment up to max 100 mg bid: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• rilpivirine
Aqvesme (mitapivat)

+

rilpivirine

1 interaction

Avoid/Use Alternative

mitapivat + rilpivirine

avoid combo: combo may decr. rilpivirine levels, efficacy (hepatic metabolism induced)

• rilzabrutinib
Aqvesme (mitapivat)

+

rilzabrutinib

1 interaction

Avoid/Use Alternative

mitapivat + rilzabrutinib

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. rilzabrutinib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• rimegepant
Aqvesme (mitapivat)

+

rimegepant

1 interaction

Avoid/Use Alternative

mitapivat + rimegepant

avoid combo: combo may decr. rimegepant levels, efficacy (hepatic metabolism induced)

• ripretinib
Aqvesme (mitapivat)

+

ripretinib

1 interaction

Avoid/Use Alternative

mitapivat + ripretinib

use alternative or incr. ripretinib dose to 150 mg bid: combo may decr. ripretinib and active metabolite levels, efficacy (hepatic metabolism induced)

• ritonavir
Aqvesme (mitapivat)

+

ritonavir

1 interaction

Avoid/Use Alternative

mitapivat + ritonavir

avoid combo: combo may incr. or decr. mitapivat levels, incr. risk of adverse effects or decr. efficacy; may decr. ritonavir levels, efficacy (hepatic metabolism altered; hepatic metabolism induced)

• rivaroxaban
Aqvesme (mitapivat)

+

rivaroxaban

1 interaction

Avoid/Use Alternative

mitapivat + rivaroxaban

avoid combo if also combined w/ strong CYP3A4 inhibitor or P-gp inducer; use alternative if CrCl <80 and combined w/ moderate CYP3A4 inhibitor; otherwise, monitor bleeding s/sx: combo may incr. or decr. rivaroxaban levels, incr. risk of bleeding (including life-threatening), other adverse effects or decr. efficacy (P-gp-mediated transport possibly inhibited, hepatic metabolism induced)

• roflumilast
Aqvesme (mitapivat)

+

roflumilast

1 interaction

Avoid/Use Alternative

mitapivat + roflumilast

consider alternative: combo may decr. roflumilast levels, efficacy (hepatic metabolism induced)

• rolapitant
Aqvesme (mitapivat)

+

rolapitant

1 interaction

Avoid/Use Alternative

mitapivat + rolapitant

consider alternative: combo may decr. rolapitant levels, efficacy (hepatic metabolism induced)

• sacituzumab govitecan
Aqvesme (mitapivat)

+

sacituzumab govitecan

1 interaction

Avoid/Use Alternative

mitapivat + sacituzumab govitecan

avoid combo: combo may decr. SN-38 levels, efficacy (UGT possibly induced, SN-38 active small molecule moiety of sacituzumab govitecan)

• samidorphan
Aqvesme (mitapivat)

+

samidorphan

1 interaction

Avoid/Use Alternative

mitapivat + samidorphan

consider alternative: combo may decr. samidorphan levels, efficacy (hepatic metabolism induced)

• sebetralstat
Aqvesme (mitapivat)

+

sebetralstat

1 interaction

Avoid/Use Alternative

mitapivat + sebetralstat

avoid combo: combo may decr. sebetralstat levels, efficacy (hepatic metabolism induced)

• segesterone (contraceptive)
Aqvesme (mitapivat)

+

segesterone (contraceptive)

1 interaction

Avoid/Use Alternative

mitapivat + segesterone (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after mitapivat tx: combo may decr. segesterone levels, contraceptive efficacy (hepatic metabolism induced)

• selpercatinib
Aqvesme (mitapivat)

+

selpercatinib

1 interaction

Avoid/Use Alternative

mitapivat + selpercatinib

avoid combo: combo may decr. selpercatinib levels, efficacy (hepatic metabolism induced)

• selumetinib
Aqvesme (mitapivat)

+

selumetinib

1 interaction

Avoid/Use Alternative

mitapivat + selumetinib

avoid combo: combo may decr. selumetinib levels, efficacy (hepatic metabolism induced)

• sevabertinib
Aqvesme (mitapivat)

+

sevabertinib

1 interaction

Avoid/Use Alternative

mitapivat + sevabertinib

avoid combo: combo may decr. sevabertinib levels, efficacy (hepatic metabolism induced)

• simvastatin
Aqvesme (mitapivat)

+

simvastatin

1 interaction

Avoid/Use Alternative

mitapivat + simvastatin

consider alternative: combo may decr. simvastatin levels, efficacy (hepatic metabolism induced)

• sirolimus albumin-bound
Aqvesme (mitapivat)

+

sirolimus albumin-bound

1 interaction

Avoid/Use Alternative

mitapivat + sirolimus albumin-bound

avoid combo: combo may incr. or decr. sirolimus albumin-bound levels, incr. risk of serious infection, myelosuppression, bleeding (including life-threatening), other adverse effects or decr. efficacy (hepatic metabolism induced, P-gp-mediated transport possibly inhibited)

• sonidegib
Aqvesme (mitapivat)

+

sonidegib

1 interaction

Avoid/Use Alternative

mitapivat + sonidegib

avoid combo: combo may decr. sonidegib levels, efficacy (hepatic metabolism induced)

• sotorasib
Aqvesme (mitapivat)

+

sotorasib

1 interaction

Avoid/Use Alternative

mitapivat + sotorasib

consider alternative; otherwise, monitor Hgb and consider mitapivat dose adjustment up to max 100 mg bid: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• St. John's wort
Aqvesme (mitapivat)

+

St. John's wort

1 interaction

Avoid/Use Alternative

mitapivat + St. John's wort

avoid combo: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• sufentanil
Aqvesme (mitapivat)

+

sufentanil

1 interaction

Avoid/Use Alternative

mitapivat + sufentanil

use alternative or consider sufentanil dose adjustment: combo may decr. sufentanil levels, efficacy (hepatic metabolism induced)

• sunvozertinib
Aqvesme (mitapivat)

+

sunvozertinib

1 interaction

Avoid/Use Alternative

mitapivat + sunvozertinib

use alternative or monitor Hgb; incr. sunvozertinib dose to 400 mg once daily: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• suzetrigine
Aqvesme (mitapivat)

+

suzetrigine

1 interaction

Avoid/Use Alternative

mitapivat + suzetrigine

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• tadalafil
Aqvesme (mitapivat)

+

tadalafil

1 interaction

Avoid/Use Alternative

mitapivat + tadalafil

PULMONARY HTN: consider alternative; ERECTILE DYSFUNCTION and BENIGN PROSTATIC HYPERPLASIA: caution advised: combo may decr. tadalafil levels, efficacy (hepatic metabolism induced)

• taletrectinib
Aqvesme (mitapivat)

+

taletrectinib

1 interaction

Avoid/Use Alternative

mitapivat + taletrectinib

avoid combo: combo may decr. taletrectinib levels, efficacy (hepatic metabolism induced)

• tamoxifen
Aqvesme (mitapivat)

+

tamoxifen

1 interaction

Avoid/Use Alternative

mitapivat + tamoxifen

avoid combo: combo may decr. tamoxifen and active metabolite levels, efficacy (hepatic metabolism induced)

• tasimelteon
Aqvesme (mitapivat)

+

tasimelteon

1 interaction

Avoid/Use Alternative

mitapivat + tasimelteon

consider alternative: combo may decr. tasimelteon levels, efficacy (hepatic metabolism induced)

• tazemetostat
Aqvesme (mitapivat)

+

tazemetostat

1 interaction

Avoid/Use Alternative

mitapivat + tazemetostat

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• tezacaftor/ivacaftor
Aqvesme (mitapivat)

+

tezacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

mitapivat + tezacaftor/ ivacaftor

avoid combo: combo may decr. tezacaftor/ivacaftor levels, efficacy (hepatic metabolism induced)

• thiotepa
Aqvesme (mitapivat)

+

thiotepa

1 interaction

Avoid/Use Alternative

mitapivat + thiotepa

use alternative or monitor CBC: combo may decr. thiotepa levels, efficacy; may incr. thiotepa active metabolite levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism induced, incr. metabolite formation)

• ticagrelor
Aqvesme (mitapivat)

+

ticagrelor

1 interaction

Avoid/Use Alternative

mitapivat + ticagrelor

avoid combo: combo may decr. ticagrelor levels, efficacy (hepatic metabolism induced)

• tipranavir
Aqvesme (mitapivat)

+

tipranavir

1 interaction

Avoid/Use Alternative

mitapivat + tipranavir

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. tipranavir levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• tofacitinib
Aqvesme (mitapivat)

+

tofacitinib

1 interaction

Avoid/Use Alternative

mitapivat + tofacitinib

consider alternative: combo may decr. tofacitinib levels, efficacy (hepatic metabolism induced)

• tolvaptan
Aqvesme (mitapivat)

+

tolvaptan

1 interaction

Avoid/Use Alternative

mitapivat + tolvaptan

consider alternative: combo may decr. tolvaptan levels, efficacy (hepatic metabolism induced)

• topotecan
Aqvesme (mitapivat)

+

topotecan

1 interaction

Avoid/Use Alternative

mitapivat + topotecan

avoid combo w/ oral topotecan: combo may incr. topotecan levels, risk of serious infection, myelosuppression, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• toremifene
Aqvesme (mitapivat)

+

toremifene

1 interaction

Avoid/Use Alternative

mitapivat + toremifene

consider alternative: combo may decr. toremifene levels, efficacy (hepatic metabolism induced)

• tramadol
Aqvesme (mitapivat)

+

tramadol

1 interaction

Avoid/Use Alternative

mitapivat + tramadol

use alternative or monitor withdrawal sx: combo may decr. tramadol levels, efficacy (hepatic metabolism induced)

• tucatinib
Aqvesme (mitapivat)

+

tucatinib

1 interaction

Avoid/Use Alternative

mitapivat + tucatinib

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. tucatinib levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• ulipristal (post-coital contraceptive)
Aqvesme (mitapivat)

+

ulipristal (post-coital contraceptive)

1 interaction

Avoid/Use Alternative

mitapivat + ulipristal (post-coital contraceptive)

avoid combo: combo may decr. ulipristal levels, post-coital contraceptive efficacy (hepatic metabolism induced)

• valbenazine
Aqvesme (mitapivat)

+

valbenazine

1 interaction

Avoid/Use Alternative

mitapivat + valbenazine

avoid combo: combo may decr. valbenazine levels, efficacy (hepatic metabolism induced)

• vanzacaftor/tezacaftor/deutivacaftor
Aqvesme (mitapivat)

+

vanzacaftor/ tezacaftor/ deutivacaftor

1 interaction

Avoid/Use Alternative

mitapivat + vanzacaftor/ tezacaftor/ deutivacaftor

avoid combo: combo may decr. vanzacaftor/tezacaftor/deutivacaftor levels, efficacy (hepatic metabolism induced)

• velpatasvir
Aqvesme (mitapivat)

+

velpatasvir

1 interaction

Avoid/Use Alternative

mitapivat + velpatasvir

avoid combo: combo may decr. velpatasvir levels, efficacy (hepatic metabolism induced)

• venetoclax
Aqvesme (mitapivat)

+

venetoclax

1 interaction

Avoid/Use Alternative

mitapivat + venetoclax

avoid combo: combo may incr. or decr. venetoclax levels, incr. risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects or decr. efficacy (hepatic metabolism induced, P-gp-mediated transport possibly inhibited)

• verapamil
Aqvesme (mitapivat)

+

verapamil

1 interaction

Avoid/Use Alternative

mitapivat + verapamil

THALASSEMIA: avoid combo; HEMOLYTIC ANEMIA: use alternative or monitor Hgb; adjust max mitapivat dose to 20 mg bid: combo may incr. mitapivat levels, risk of adverse effects; may decr. verapamil levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• voclosporin
Aqvesme (mitapivat)

+

voclosporin

1 interaction

Avoid/Use Alternative

mitapivat + voclosporin

avoid combo: combo may decr. voclosporin levels, efficacy (hepatic metabolism induced)

• vonoprazan
Aqvesme (mitapivat)

+

vonoprazan

1 interaction

Avoid/Use Alternative

mitapivat + vonoprazan

avoid combo: combo may decr. vonoprazan levels, efficacy (hepatic metabolism induced)

• voriconazole
Aqvesme (mitapivat)

+

voriconazole

1 interaction

Avoid/Use Alternative

mitapivat + voriconazole

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. voriconazole levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• voxilaprevir
Aqvesme (mitapivat)

+

voxilaprevir

1 interaction

Avoid/Use Alternative

mitapivat + voxilaprevir

avoid combo: combo may decr. voxilaprevir levels, efficacy (hepatic metabolism induced)

• zanubrutinib
Aqvesme (mitapivat)

+

zanubrutinib

1 interaction

Avoid/Use Alternative

mitapivat + zanubrutinib

use alternative or monitor Hgb; incr. zanubrutinib dose to 320 mg bid: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• ziftomenib
Aqvesme (mitapivat)

+

ziftomenib

1 interaction

Avoid/Use Alternative

mitapivat + ziftomenib

avoid combo: combo may decr. ziftomenib levels, efficacy (hepatic metabolism induced)

• zuranolone
Aqvesme (mitapivat)

+

zuranolone

1 interaction

Avoid/Use Alternative

mitapivat + zuranolone

avoid combo: combo may decr. zuranolone levels, efficacy (hepatic metabolism induced)

Monitor/Modify Tx

• abiraterone acetate
Aqvesme (mitapivat)

+

abiraterone acetate

1 interaction

Monitor/Modify Tx

mitapivat + abiraterone acetate

if abiraterone coformulated w/ niraparib, caution advised; otherwise, consider abiraterone dose adjustment: combo may decr. abiraterone levels, efficacy (hepatic metabolism induced)

• acalabrutinib
Aqvesme (mitapivat)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

mitapivat + acalabrutinib

consider acalabrutinib dose adjustment: combo may decr. acalabrutinib levels, efficacy (hepatic metabolism induced)

• afatinib
Aqvesme (mitapivat)

+

afatinib

1 interaction

Monitor/Modify Tx

mitapivat + afatinib

decr. afatinib dose by 10 mg/day if not tolerated: combo may incr. afatinib levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

• aficamten
Aqvesme (mitapivat)

+

aficamten

1 interaction

Monitor/Modify Tx

mitapivat + aficamten

monitor cardiac fxn, incl. LVEF; when discontinuing mitapivat, decr. aficamten dose as follows: if on aficamten 20 mg qd, decr. to 10 mg qd; if on aficamten 15 mg or 10 mg qd, decr. to 5 mg qd; if on aficamten 5 mg qd, continue 5 mg qd: combo may decr. aficamten levels, efficacy (hepatic metabolism induced)

• aminophylline
Aqvesme (mitapivat)

+

aminophylline

1 interaction

Monitor/Modify Tx

mitapivat + aminophylline

monitor theophylline levels: combo may decr. theophylline levels, efficacy (hepatic metabolism induced, aminophylline converted to theophylline)

• amlodipine
Aqvesme (mitapivat)

+

amlodipine

1 interaction

Monitor/Modify Tx

mitapivat + amlodipine

monitor BP: combo may decr. amlodipine levels, efficacy (hepatic metabolism induced)

• apixaban
Aqvesme (mitapivat)

+

apixaban

1 interaction

Monitor/Modify Tx

mitapivat + apixaban

monitor bleeding s/sx; consider decr. apixaban dose adjustment: combo may incr. or decr. apixaban levels, incr. risk of bleeding, other adverse effects or decr. efficacy (hepatic metabolism induced, P-gp-mediated transport possibly inhibited)

• armodafinil
Aqvesme (mitapivat)

+

armodafinil

1 interaction

Monitor/Modify Tx

mitapivat + armodafinil

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• atorvastatin
Aqvesme (mitapivat)

+

atorvastatin

1 interaction

Monitor/Modify Tx

mitapivat + atorvastatin

monitor CK, myopathy sx: combo may incr. or decr. atorvastatin levels, incr. risk of myopathy, rhabdomyolysis or decr. efficacy (hepatic metabolism induced, P-gp-mediated transport possibly inhibited)

• avatrombopag
Aqvesme (mitapivat)

+

avatrombopag

1 interaction

Monitor/Modify Tx

mitapivat + avatrombopag

CHRONIC IMMUNE THROMBOCYTOPENIA: monitor platelets; if avatrombopag tablet also combined w/ moderate or strong CYP2C9 inducer, incr. start dose to 40 mg qd; if avatrombopag sprinkle also combined w/ moderate or strong CYP2C9 inducer, incr. start dose to 20 mg qd; CHRONIC LIVER DZ: monitor platelets: combo may decr. avatrombopag levels, efficacy (hepatic metabolism induced)

• belzutifan
Aqvesme (mitapivat)

+

belzutifan

1 interaction

Monitor/Modify Tx

mitapivat + belzutifan

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• bexarotene
Aqvesme (mitapivat)

+

bexarotene

1 interaction

Monitor/Modify Tx

mitapivat + bexarotene

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• brexpiprazole
Aqvesme (mitapivat)

+

brexpiprazole

1 interaction

Monitor/Modify Tx

mitapivat + brexpiprazole

consider incr. brexpiprazole dose: combo may decr. brexpiprazole levels, efficacy (hepatic metabolism induced)

• butorphanol
Aqvesme (mitapivat)

+

butorphanol

1 interaction

Monitor/Modify Tx

mitapivat + butorphanol

monitor for withdrawal sx: combo may decr. butorphanol levels, efficacy (hepatic metabolism induced)

• calcitriol
Aqvesme (mitapivat)

+

calcitriol

1 interaction

Monitor/Modify Tx

mitapivat + calcitriol

monitor vitamin D levels: combo may decr. vitamin D levels, efficacy (hepatic metabolism induced)

• cholecalciferol (vitamin D3)
Aqvesme (mitapivat)

+

cholecalciferol (vitamin D3)

1 interaction

Monitor/Modify Tx

mitapivat + cholecalciferol (vitamin D3)

monitor vitamin D levels: combo may decr. vitamin D levels, efficacy (hepatic metabolism induced)

• clobazam
Aqvesme (mitapivat)

+

clobazam

1 interaction

Monitor/Modify Tx

mitapivat + clobazam

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• clozapine
Aqvesme (mitapivat)

+

clozapine

1 interaction

Monitor/Modify Tx

mitapivat + clozapine

consider clozapine dose adjustment: combo may decr. clozapine levels, efficacy (hepatic metabolism induced)

• crinecerfont
Aqvesme (mitapivat)

+

crinecerfont

1 interaction

Monitor/Modify Tx

mitapivat + crinecerfont

ADULTS: keep 100 mg morning dose unchanged, incr. crinecerfont evening dose to 200 mg; PEDS 4 YO AND OLDER: incr. crinecerfont dose based on weight as follows: if 10-19 kg, keep 25 mg morning dose unchanged, incr. crinecerfont evening dose to 50 mg; if 20-54 kg, keep 50 mg morning dose unchanged, incr. crinecerfont evening dose to 100 mg; if 55 kg or greater, keep 100 mg morning dose unchanged, incr. crinecerfont evening dose to 200 mg: combo may decr. crinecerfont levels, efficacy (hepatic metabolism induced)

• cyclophosphamide
Aqvesme (mitapivat)

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

mitapivat + cyclophosphamide

monitor CBC, renal, cardiac fxn: combo may incr. cyclophosphamide active metabolite levels, risk of serious infection, myelosuppression, nephrotoxicity, cardiotoxicity, other adverse effects (hepatic metabolism possibly induced, incr. active metabolite formation)

• danshen
Aqvesme (mitapivat)

+

danshen

1 interaction

Monitor/Modify Tx

mitapivat + danshen

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• deferasirox
Aqvesme (mitapivat)

+

deferasirox

1 interaction

Monitor/Modify Tx

mitapivat + deferasirox

monitor serum ferritin levels: combo may decr. deferasirox levels, efficacy (UGT possibly induced)

• dexamethasone
Aqvesme (mitapivat)

+

dexamethasone

1 interaction

Monitor/Modify Tx

mitapivat + dexamethasone

monitor Hgb: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• dicloxacillin
Aqvesme (mitapivat)

+

dicloxacillin

1 interaction

Monitor/Modify Tx

mitapivat + dicloxacillin

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• digoxin
Aqvesme (mitapivat)

+

digoxin

1 interaction

Monitor/Modify Tx

mitapivat + digoxin

monitor digoxin levels, HR; decr. digoxin frequency or dose by 15-30%: combo may incr. digoxin levels, risk of bradycardia, AV block, other adverse effects (P-gp-mediated transport possibly inhibited)

• disopyramide
Aqvesme (mitapivat)

+

disopyramide

1 interaction

Monitor/Modify Tx

mitapivat + disopyramide

monitor disopyramide levels: combo may decr. disopyramide levels, efficacy (hepatic metabolism induced)

• doxercalciferol
Aqvesme (mitapivat)

+

doxercalciferol

1 interaction

Monitor/Modify Tx

mitapivat + doxercalciferol

monitor calcium, iPTH: combo may alter doxercalciferol and active metabolite levels, efficacy (hepatic metabolism induced, net effect on vitamin D activation/inactivation unknown)

• echinacea
Aqvesme (mitapivat)

+

echinacea

1 interaction

Monitor/Modify Tx

mitapivat + echinacea

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• edoxaban
Aqvesme (mitapivat)

+

edoxaban

1 interaction

Monitor/Modify Tx

mitapivat + edoxaban

monitor bleeding s/sx: combo may incr. edoxaban levels, risk of bleeding, other adverse effects (P-gp-mediated transport possibly inhibited)

• elafibranor
Aqvesme (mitapivat)

+

elafibranor

1 interaction

Monitor/Modify Tx

mitapivat + elafibranor

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• enasidenib
Aqvesme (mitapivat)

+

enasidenib

1 interaction

Monitor/Modify Tx

mitapivat + enasidenib

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• enfortumab vedotin
Aqvesme (mitapivat)

+

enfortumab vedotin

1 interaction

Monitor/Modify Tx

mitapivat + enfortumab vedotin

if also combined w/ strong CYP3A4 inhibitor, monitor CBC, glucose; otherwise, caution advised: combo may incr. or decr. enfortumab vedotin levels, incr. risk of myelosuppression, neuropathy, hyperglycemia, other adverse effects or decr. efficacy (hepatic metabolism induced, P-gp-mediated transport possibly inhibited)

• eslicarbazepine acetate
Aqvesme (mitapivat)

+

eslicarbazepine acetate

1 interaction

Monitor/Modify Tx

mitapivat + eslicarbazepine acetate

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• ethosuximide
Aqvesme (mitapivat)

+

ethosuximide

1 interaction

Monitor/Modify Tx

mitapivat + ethosuximide

monitor ethosuximide levels: combo may decr. ethosuximide levels, efficacy (hepatic metabolism induced)

• felbamate
Aqvesme (mitapivat)

+

felbamate

1 interaction

Monitor/Modify Tx

mitapivat + felbamate

monitor Hgb: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• fludrocortisone
Aqvesme (mitapivat)

+

fludrocortisone

1 interaction

Monitor/Modify Tx

mitapivat + fludrocortisone

consider fludrocortisone dose adjustment: combo may decr. fludrocortisone levels, efficacy (hepatic metabolism induced)

• garlic
Aqvesme (mitapivat)

+

garlic

1 interaction

Monitor/Modify Tx

mitapivat + garlic

monitor Hgb w/ supplemental garlic; dietary intake OK: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• ginkgo
Aqvesme (mitapivat)

+

ginkgo

1 interaction

Monitor/Modify Tx

mitapivat + ginkgo

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• ginseng, Asian
Aqvesme (mitapivat)

+

ginseng, Asian

1 interaction

Monitor/Modify Tx

mitapivat + ginseng, Asian

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• glycerol phenylbutyrate
Aqvesme (mitapivat)

+

glycerol phenylbutyrate

1 interaction

Monitor/Modify Tx

mitapivat + glycerol phenylbutyrate

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• griseofulvin
Aqvesme (mitapivat)

+

griseofulvin

1 interaction

Monitor/Modify Tx

mitapivat + griseofulvin

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• guanfacine
Aqvesme (mitapivat)

+

guanfacine

1 interaction

Monitor/Modify Tx

mitapivat + guanfacine

consider incr. guanfacine ER dose up to double, consider incr. dose for immed.-release form: combo may decr. guanfacine levels, efficacy (hepatic metabolism induced)

• haloperidol
Aqvesme (mitapivat)

+

haloperidol

1 interaction

Monitor/Modify Tx

mitapivat + haloperidol

consider haloperidol dose adjustment: combo may decr. haloperidol levels, efficacy (hepatic metabolism induced)

• hydrocortisone
Aqvesme (mitapivat)

+

hydrocortisone

1 interaction

Monitor/Modify Tx

mitapivat + hydrocortisone

consider hydrocortisone dose adjustment: combo may decr. hydrocortisone levels, efficacy (hepatic metabolism induced)

• ifosfamide
Aqvesme (mitapivat)

+

ifosfamide

1 interaction

Monitor/Modify Tx

mitapivat + ifosfamide

monitor CBC, renal, cardiac fxn; consider ifosfamide dose adjustment: combo may incr. ifosfamide active and toxic metabolite levels, risk of myelosuppression, serious infection, encephalopathy, nephrotoxicity, cardiotoxicity, other adverse effects (hepatic metabolism induced, incr. metabolite formation)

• imipramine
Aqvesme (mitapivat)

+

imipramine

1 interaction

Monitor/Modify Tx

mitapivat + imipramine

monitor imipramine levels: combo may decr. imipramine levels, efficacy (hepatic metabolism induced)

• lapatinib
Aqvesme (mitapivat)

+

lapatinib

1 interaction

Monitor/Modify Tx

mitapivat + lapatinib

consider lapatinib dose adjustment: combo may decr. lapatinib levels, efficacy (hepatic metabolism induced)

• levothyroxine
Aqvesme (mitapivat)

+

levothyroxine

1 interaction

Monitor/Modify Tx

mitapivat + levothyroxine

monitor thyroid fxn: combo may decr. thyroid hormone levels, efficacy (UGT possibly induced)

• liothyronine
Aqvesme (mitapivat)

+

liothyronine

1 interaction

Monitor/Modify Tx

mitapivat + liothyronine

monitor thyroid fxn: combo may decr. thyroid hormone levels, efficacy (UGT possibly induced)

• lurasidone
Aqvesme (mitapivat)

+

lurasidone

1 interaction

Monitor/Modify Tx

mitapivat + lurasidone

consider lurasidone dose adjustment: combo may decr. lurasidone levels, efficacy (hepatic metabolism induced)

• macimorelin
Aqvesme (mitapivat)

+

macimorelin

1 interaction

Monitor/Modify Tx

mitapivat + macimorelin

D/C macimorelin, allowing sufficient washout time before diagnostic test: combo may decr. macimorelin levels, result in false positive test (hepatic metabolism induced)

• mavorixafor
Aqvesme (mitapivat)

+

mavorixafor

1 interaction

Monitor/Modify Tx

mitapivat + mavorixafor

monitor ECG: combo may incr. or decr. mavorixafor levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (P-gp-mediated transport possibly inhibited, hepatic metabolism induced)

• meropenem
Aqvesme (mitapivat)

+

meropenem

1 interaction

Monitor/Modify Tx

mitapivat + meropenem

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism possibly induced)

• mirtazapine
Aqvesme (mitapivat)

+

mirtazapine

1 interaction

Monitor/Modify Tx

mitapivat + mirtazapine

consider mirtazapine dose adjustment: combo may decr. mirtazapine levels, efficacy (hepatic metabolism induced)

• morphine
Aqvesme (mitapivat)

+

morphine

1 interaction

Monitor/Modify Tx

mitapivat + morphine

monitor respiratory rate; consider decr. dose of one or both drugs: combo may incr. morphine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (P-gp-mediated transport possibly inhibited)

• nimodipine
Aqvesme (mitapivat)

+

nimodipine

1 interaction

Monitor/Modify Tx

mitapivat + nimodipine

monitor BP: combo may decr. nimodipine levels, efficacy (hepatic metabolism induced)

• nortriptyline
Aqvesme (mitapivat)

+

nortriptyline

1 interaction

Monitor/Modify Tx

mitapivat + nortriptyline

monitor nortriptyline levels: combo may decr. nortriptyline levels, efficacy (hepatic metabolism induced)

• odevixibat
Aqvesme (mitapivat)

+

odevixibat

1 interaction

Monitor/Modify Tx

mitapivat + odevixibat

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• orforglipron
Aqvesme (mitapivat)

+

orforglipron

1 interaction

Monitor/Modify Tx

mitapivat + orforglipron

consider orforglipron dose adjustment: combo may decr. orforglipron levels, efficacy (hepatic metabolism induced)

• oxcarbazepine
Aqvesme (mitapivat)

+

oxcarbazepine

1 interaction

Monitor/Modify Tx

mitapivat + oxcarbazepine

monitor Hgb: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• paltusotine
Aqvesme (mitapivat)

+

paltusotine

1 interaction

Monitor/Modify Tx

mitapivat + paltusotine

may incr. usual paltusotine dose up to 2-fold, not to exceed 120 mg daily: combo may decr. paltusotine levels, efficacy (hepatic metabolism induced)

• perampanel
Aqvesme (mitapivat)

+

perampanel

1 interaction

Monitor/Modify Tx

mitapivat + perampanel

incr. perampanel start dose to 4 mg/day; monitor Hgb if on perampanel 12 mg/day: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• pioglitazone
Aqvesme (mitapivat)

+

pioglitazone

1 interaction

Monitor/Modify Tx

mitapivat + pioglitazone

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• prednisone
Aqvesme (mitapivat)

+

prednisone

1 interaction

Monitor/Modify Tx

mitapivat + prednisone

monitor Hgb: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• quetiapine
Aqvesme (mitapivat)

+

quetiapine

1 interaction

Monitor/Modify Tx

mitapivat + quetiapine

consider quetiapine dose adjustment: combo may decr. quetiapine levels, efficacy (hepatic metabolism induced)

• quinidine (antiarrhythmic)
Aqvesme (mitapivat)

+

quinidine (antiarrhythmic)

1 interaction

Monitor/Modify Tx

mitapivat + quinidine (antiarrhythmic)

monitor quinidine levels, ECG: combo may incr. or decr. quinidine levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (hepatic metabolism induced, P-gp-mediated transport possibly inhibited)

• repaglinide
Aqvesme (mitapivat)

+

repaglinide

1 interaction

Monitor/Modify Tx

mitapivat + repaglinide

monitor glucose: combo may decr. repaglinide levels, efficacy (hepatic metabolism induced)

• rufinamide
Aqvesme (mitapivat)

+

rufinamide

1 interaction

Monitor/Modify Tx

mitapivat + rufinamide

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• sarilumab
Aqvesme (mitapivat)

+

sarilumab

1 interaction

Monitor/Modify Tx

mitapivat + sarilumab

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C)

• sildenafil
Aqvesme (mitapivat)

+

sildenafil

1 interaction

Monitor/Modify Tx

mitapivat + sildenafil

PULMONARY HTN: consider sildenafil dose adjustment; ERECTILE DYSFUNCTION: caution advised: combo may decr. sildenafil levels, efficacy (hepatic metabolism induced)

• sirolimus
Aqvesme (mitapivat)

+

sirolimus

1 interaction

Monitor/Modify Tx

mitapivat + sirolimus

monitor sirolimus levels: combo may incr. or decr. sirolimus levels, incr. risk of serious infection, other adverse effects or decr. efficacy (hepatic metabolism induced, P-gp-mediated transport possibly inhibited)

• stiripentol
Aqvesme (mitapivat)

+

stiripentol

1 interaction

Monitor/Modify Tx

mitapivat + stiripentol

consider stiripentol dose adjustment; monitor Hgb: combo may decr. levels of both drugs, efficacy (hepatic metabolism possibly induced)

• tacrolimus
Aqvesme (mitapivat)

+

tacrolimus

1 interaction

Monitor/Modify Tx

mitapivat + tacrolimus

monitor tacrolimus levels, ECG, renal fxn: combo may incr. or decr. tacrolimus levels, incr. risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, other adverse effects or decr. efficacy (hepatic metabolism induced, P-gp-mediated transport possibly inhibited)

• talazoparib
Aqvesme (mitapivat)

+

talazoparib

1 interaction

Monitor/Modify Tx

mitapivat + talazoparib

monitor CBC: combo may incr. talazoparib levels, risk of myelosuppression, other adverse effects (P-gp-mediated transport possibly inhibited)

• tecovirimat
Aqvesme (mitapivat)

+

tecovirimat

1 interaction

Monitor/Modify Tx

mitapivat + tecovirimat

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• telotristat ethyl
Aqvesme (mitapivat)

+

telotristat ethyl

1 interaction

Monitor/Modify Tx

mitapivat + telotristat ethyl

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• temsirolimus
Aqvesme (mitapivat)

+

temsirolimus

1 interaction

Monitor/Modify Tx

mitapivat + temsirolimus

consider temsirolimus dose adjustment: combo may decr. temsirolimus and active metabolite sirolimus levels, efficacy (hepatic metabolism induced)

• tenofovir alafenamide
Aqvesme (mitapivat)

+

tenofovir alafenamide

1 interaction

Monitor/Modify Tx

mitapivat + tenofovir alafenamide

if tenofovir alafenamide not admin. w/ cobicistat, monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• tenofovir disoproxil
Aqvesme (mitapivat)

+

tenofovir disoproxil

1 interaction

Monitor/Modify Tx

mitapivat + tenofovir disoproxil

monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut P-gp-mediated transport possibly inhibited)

• theophylline
Aqvesme (mitapivat)

+

theophylline

1 interaction

Monitor/Modify Tx

mitapivat + theophylline

monitor theophylline levels: combo may decr. theophylline levels, efficacy (hepatic metabolism induced)

• thyroid
Aqvesme (mitapivat)

+

thyroid

1 interaction

Monitor/Modify Tx

mitapivat + thyroid

monitor thyroid fxn: combo may decr. thyroid hormone levels, efficacy (UGT possibly induced)

• tiagabine
Aqvesme (mitapivat)

+

tiagabine

1 interaction

Monitor/Modify Tx

mitapivat + tiagabine

consider tiagabine dose adjustment if not on concurrent enzyme-inducing AEDs; titrate tiagabine dose to effect if already on enzyme-inducing AEDs: combo may decr. tiagabine levels, efficacy (hepatic metabolism induced; further induction possible if on concurrent enzyme-inducing AEDs)

• tocilizumab
Aqvesme (mitapivat)

+

tocilizumab

1 interaction

Monitor/Modify Tx

mitapivat + tocilizumab

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes)

• topiramate
Aqvesme (mitapivat)

+

topiramate

1 interaction

Monitor/Modify Tx

mitapivat + topiramate

monitor Hgb, especially w/ topiramate doses >200 mg/day: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• tovorafenib
Aqvesme (mitapivat)

+

tovorafenib

1 interaction

Monitor/Modify Tx

mitapivat + tovorafenib

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism induced)

• ubrogepant
Aqvesme (mitapivat)

+

ubrogepant

1 interaction

Monitor/Modify Tx

mitapivat + ubrogepant

consider ubrogepant dose adjustment: combo may incr. or decr. ubrogepant levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport possibly inhibited, hepatic metabolism induced)

• vaborbactam
Aqvesme (mitapivat)

+

vaborbactam

1 interaction

Monitor/Modify Tx

mitapivat + vaborbactam

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism possibly induced)

• vamorolone
Aqvesme (mitapivat)

+

vamorolone

1 interaction

Monitor/Modify Tx

mitapivat + vamorolone

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism possibly induced)

• vemurafenib
Aqvesme (mitapivat)

+

vemurafenib

1 interaction

Monitor/Modify Tx

mitapivat + vemurafenib

monitor Hgb: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• vilazodone
Aqvesme (mitapivat)

+

vilazodone

1 interaction

Monitor/Modify Tx

mitapivat + vilazodone

consider vilazodone dose adjustment: combo may decr. vilazodone levels, efficacy (hepatic metabolism induced)

• vinblastine
Aqvesme (mitapivat)

+

vinblastine

1 interaction

Monitor/Modify Tx

mitapivat + vinblastine

monitor Hgb: combo may decr. levels of both drugs, efficacy (hepatic metabolism induced)

• vorasidenib
Aqvesme (mitapivat)

+

vorasidenib

1 interaction

Monitor/Modify Tx

mitapivat + vorasidenib

monitor Hgb: combo may decr. mitapivat levels, efficacy (hepatic metabolism possibly induced)

• vortioxetine
Aqvesme (mitapivat)

+

vortioxetine

1 interaction

Monitor/Modify Tx

mitapivat + vortioxetine

consider vortioxetine dose adjustment: combo may decr. vortioxetine levels, efficacy (hepatic metabolism induced)

• warfarin
Aqvesme (mitapivat)

+

warfarin

1 interaction

Monitor/Modify Tx

mitapivat + warfarin

monitor INR: combo may decr. warfarin levels, efficacy (hepatic metabolism induced)

• zonisamide
Aqvesme (mitapivat)

+

zonisamide

1 interaction

Monitor/Modify Tx

mitapivat + zonisamide

consider zonisamide dose adjustment: combo may decr. zonisamide levels, efficacy (hepatic metabolism induced)

Caution Advised

• albendazole
Aqvesme (mitapivat)

+

albendazole

1 interaction

Caution Advised

mitapivat + albendazole

caution advised: combo may decr. albendazole levels, efficacy (hepatic metabolism induced)

• aliskiren
Aqvesme (mitapivat)

+

aliskiren

1 interaction

Caution Advised

mitapivat + aliskiren

caution advised: combo may decr. aliskiren levels, efficacy (hepatic metabolism induced)

• alprazolam
Aqvesme (mitapivat)

+

alprazolam

1 interaction

Caution Advised

mitapivat + alprazolam

caution advised: combo may decr. alprazolam levels, efficacy (hepatic metabolism induced)

• amiodarone
Aqvesme (mitapivat)

+

amiodarone

1 interaction

Caution Advised

mitapivat + amiodarone

caution advised: combo may decr. amiodarone levels, efficacy (hepatic metabolism induced)

• apremilast
Aqvesme (mitapivat)

+

apremilast

1 interaction

Caution Advised

mitapivat + apremilast

caution advised: combo may decr. apremilast levels, efficacy (hepatic metabolism induced)

• aripiprazole bimonthly injection
Aqvesme (mitapivat)

+

aripiprazole bimonthly injection

1 interaction

Caution Advised

mitapivat + aripiprazole bimonthly injection

caution advised if concurrent use >14 days: combo may decr. aripiprazole levels, efficacy (hepatic metabolism induced)

• aripiprazole lauroxil
Aqvesme (mitapivat)

+

aripiprazole lauroxil

1 interaction

Caution Advised

mitapivat + aripiprazole lauroxil

caution advised, especially if aripiprazole lauroxil 441 mg qmo: combo may decr. aripiprazole levels, efficacy (hepatic metabolism induced)

• aripiprazole monthly injection
Aqvesme (mitapivat)

+

aripiprazole monthly injection

1 interaction

Caution Advised

mitapivat + aripiprazole monthly injection

caution advised if concurrent use >14 days: combo may decr. aripiprazole levels, efficacy (hepatic metabolism induced)

• aripiprazole oral
Aqvesme (mitapivat)

+

aripiprazole oral

1 interaction

Caution Advised

mitapivat + aripiprazole oral

caution advised if concurrent use >14 days: combo may decr. aripiprazole levels, efficacy (hepatic metabolism induced)

• avanafil
Aqvesme (mitapivat)

+

avanafil

1 interaction

Caution Advised

mitapivat + avanafil

caution advised: combo may decr. avanafil levels, efficacy (hepatic metabolism induced)

• bazedoxifene
Aqvesme (mitapivat)

+

bazedoxifene

1 interaction

Caution Advised

mitapivat + bazedoxifene

caution advised: combo may decr. bazedoxifene levels, efficacy (UGT possibly induced)

• belumosudil
Aqvesme (mitapivat)

+

belumosudil

1 interaction

Caution Advised

mitapivat + belumosudil

caution advised: combo may decr. belumosudil levels, efficacy (hepatic metabolism induced)

• betamethasone
Aqvesme (mitapivat)

+

betamethasone

1 interaction

Caution Advised

mitapivat + betamethasone

caution advised: combo may decr. betamethasone levels, efficacy (hepatic metabolism induced)

• bortezomib
Aqvesme (mitapivat)

+

bortezomib

1 interaction

Caution Advised

mitapivat + bortezomib

caution advised: combo may decr. bortezomib levels, efficacy (hepatic metabolism induced)

• budesonide
Aqvesme (mitapivat)

+

budesonide

1 interaction

Caution Advised

mitapivat + budesonide

caution advised: combo may decr. budesonide levels, efficacy (hepatic metabolism induced)

• bupropion
Aqvesme (mitapivat)

+

bupropion

1 interaction

Caution Advised

mitapivat + bupropion

caution advised: combo may decr. bupropion and metabolite levels, efficacy (hepatic metabolism possibly induced)

• cannabis
Aqvesme (mitapivat)

+

cannabis

1 interaction

Caution Advised

mitapivat + cannabis

caution advised: combo may decr. cannabis levels, efficacy (hepatic metabolism induced)

• carisoprodol
Aqvesme (mitapivat)

+

carisoprodol

1 interaction

Caution Advised

mitapivat + carisoprodol

caution advised: combo may decr. carisoprodol levels, incr. active metabolite meprobamate levels, alter risk of adverse effects and efficacy (hepatic metabolism possibly induced, incr. conversion to active metabolite)

• clindamycin
Aqvesme (mitapivat)

+

clindamycin

1 interaction

Caution Advised

mitapivat + clindamycin

caution advised: combo may decr. clindamycin levels, efficacy (hepatic metabolism induced)

• copanlisib
Aqvesme (mitapivat)

+

copanlisib

1 interaction

Caution Advised

mitapivat + copanlisib

caution advised: combo may decr. copanlisib levels, efficacy (hepatic metabolism induced)

• cortisone
Aqvesme (mitapivat)

+

cortisone

1 interaction

Caution Advised

mitapivat + cortisone

caution advised: combo may decr. cortisone levels, efficacy (hepatic metabolism induced)

• dapsone
Aqvesme (mitapivat)

+

dapsone

1 interaction

Caution Advised

mitapivat + dapsone

caution advised: combo may decr. dapsone levels, incr. toxic metabolite levels, risk of hematologic adverse effects or decr. efficacy (hepatic metabolism induced, incr. toxic metabolite formation)

• dasatinib
Aqvesme (mitapivat)

+

dasatinib

1 interaction

Caution Advised

mitapivat + dasatinib

caution advised: combo may decr. dasatinib levels, efficacy (hepatic metabolism induced)

• diazepam
Aqvesme (mitapivat)

+

diazepam

1 interaction

Caution Advised

mitapivat + diazepam

caution advised: combo may decr. diazepam levels, efficacy (hepatic metabolism induced)

• drospirenone (hormone replacement)
Aqvesme (mitapivat)

+

drospirenone (hormone replacement)

1 interaction

Caution Advised

mitapivat + drospirenone (hormone replacement)

caution advised: combo may decr. drospirenone levels, efficacy (hepatic metabolism induced)

• eliglustat
Aqvesme (mitapivat)

+

eliglustat

1 interaction

Caution Advised

mitapivat + eliglustat

caution advised: combo may decr. eliglustat levels, efficacy (hepatic metabolism induced)

• esomeprazole
Aqvesme (mitapivat)

+

esomeprazole

1 interaction

Caution Advised

mitapivat + esomeprazole

caution advised: combo may decr. esomeprazole levels, efficacy (hepatic metabolism induced)

• eszopiclone
Aqvesme (mitapivat)

+

eszopiclone

1 interaction

Caution Advised

mitapivat + eszopiclone

caution advised: combo may decr. eszopiclone levels, efficacy (hepatic metabolism induced)

• ethinyl estradiol (hormone replacement)
Aqvesme (mitapivat)

+

ethinyl estradiol (hormone replacement)

1 interaction

Caution Advised

mitapivat + ethinyl estradiol (hormone replacement)

caution advised: combo may decr. ethinyl estradiol levels, efficacy (hepatic metabolism induced)

• etoposide
Aqvesme (mitapivat)

+

etoposide

1 interaction

Caution Advised

mitapivat + etoposide

caution advised: combo may decr. etoposide levels, efficacy (hepatic metabolism induced)

• etrasimod
Aqvesme (mitapivat)

+

etrasimod

1 interaction

Caution Advised

mitapivat + etrasimod

caution advised: combo may decr. etrasimod levels, efficacy (hepatic metabolism induced)

• exemestane
Aqvesme (mitapivat)

+

exemestane

1 interaction

Caution Advised

mitapivat + exemestane

caution advised: combo may decr. exemestane levels, efficacy (hepatic metabolism induced)

• fenfluramine
Aqvesme (mitapivat)

+

fenfluramine

1 interaction

Caution Advised

mitapivat + fenfluramine

caution advised: combo may decr. fenfluramine levels, efficacy (hepatic metabolism induced)

• fesoterodine
Aqvesme (mitapivat)

+

fesoterodine

1 interaction

Caution Advised

mitapivat + fesoterodine

caution advised: combo may decr. fesoterodine active metabolite levels, efficacy (hepatic metabolism induced)

• finasteride
Aqvesme (mitapivat)

+

finasteride

1 interaction

Caution Advised

mitapivat + finasteride

caution advised: combo may decr. finasteride levels, efficacy (hepatic metabolism induced)

• flibanserin
Aqvesme (mitapivat)

+

flibanserin

1 interaction

Caution Advised

mitapivat + flibanserin

caution advised: combo may decr. flibanserin levels, efficacy (hepatic metabolism induced)

• fostemsavir
Aqvesme (mitapivat)

+

fostemsavir

1 interaction

Caution Advised

mitapivat + fostemsavir

caution advised: combo may decr. temsavir levels, efficacy (hepatic metabolism induced)

• futibatinib
Aqvesme (mitapivat)

+

futibatinib

1 interaction

Caution Advised

mitapivat + futibatinib

caution advised: combo may decr. futibatinib levels, efficacy (hepatic metabolism induced)

• gefitinib
Aqvesme (mitapivat)

+

gefitinib

1 interaction

Caution Advised

mitapivat + gefitinib

caution advised: combo may decr. gefitinib levels, efficacy (hepatic metabolism induced)

• gepirone
Aqvesme (mitapivat)

+

gepirone

1 interaction

Caution Advised

mitapivat + gepirone

caution advised: combo may decr. gepirone levels, efficacy (hepatic metabolism induced)

• glyburide
Aqvesme (mitapivat)

+

glyburide

1 interaction

Caution Advised

mitapivat + glyburide

caution advised: combo may decr. glyburide levels, efficacy (hepatic metabolism induced)

• imlunestrant
Aqvesme (mitapivat)

+

imlunestrant

1 interaction

Caution Advised

mitapivat + imlunestrant

caution advised: combo may decr. imlunestrant levels, efficacy (hepatic metabolism induced)

• isotretinoin
Aqvesme (mitapivat)

+

isotretinoin

1 interaction

Caution Advised

mitapivat + isotretinoin

caution advised: combo may decr. isotretinoin levels, efficacy (hepatic metabolism induced)

• ivabradine
Aqvesme (mitapivat)

+

ivabradine

1 interaction

Caution Advised

mitapivat + ivabradine

caution advised: combo may decr. ivabradine levels, efficacy (hepatic metabolism induced)

• ixabepilone
Aqvesme (mitapivat)

+

ixabepilone

1 interaction

Caution Advised

mitapivat + ixabepilone

caution advised: combo may decr. ixabepilone levels, efficacy (hepatic metabolism induced)

• ixazomib
Aqvesme (mitapivat)

+

ixazomib

1 interaction

Caution Advised

mitapivat + ixazomib

caution advised: combo may decr. ixazomib levels, efficacy (hepatic metabolism induced)

• levonorgestrel (hormone replacement)
Aqvesme (mitapivat)

+

levonorgestrel (hormone replacement)

1 interaction

Caution Advised

mitapivat + levonorgestrel (hormone replacement)

caution advised: combo may decr. levonorgestrel levels, efficacy (hepatic metabolism induced)

• levonorgestrel intrauterine device (contraceptive)
Aqvesme (mitapivat)

+

levonorgestrel intrauterine device (contraceptive)

1 interaction

Caution Advised

mitapivat + levonorgestrel intrauterine device (contraceptive)

caution advised: combo may decr. levonorgestrel levels, contraceptive efficacy (hepatic metabolism possibly induced)

• lovastatin
Aqvesme (mitapivat)

+

lovastatin

1 interaction

Caution Advised

mitapivat + lovastatin

caution advised: combo may decr. lovastatin levels, efficacy (hepatic metabolism induced)

• maribavir
Aqvesme (mitapivat)

+

maribavir

1 interaction

Caution Advised

mitapivat + maribavir

caution advised: combo may decr. maribavir levels, efficacy (hepatic metabolism induced)

• mefloquine
Aqvesme (mitapivat)

+

mefloquine

1 interaction

Caution Advised

mitapivat + mefloquine

caution advised: combo may decr. mefloquine levels, efficacy (hepatic metabolism induced)

• methylprednisolone
Aqvesme (mitapivat)

+

methylprednisolone

1 interaction

Caution Advised

mitapivat + methylprednisolone

caution advised: combo may decr. methylprednisolone levels, efficacy (hepatic metabolism induced)

• metoclopramide
Aqvesme (mitapivat)

+

metoclopramide

1 interaction

Caution Advised

mitapivat + metoclopramide

caution advised: combo may decr. metoclopramide levels, efficacy (hepatic metabolism induced)

• moxifloxacin
Aqvesme (mitapivat)

+

moxifloxacin

1 interaction

Caution Advised

mitapivat + moxifloxacin

caution advised: combo may decr. moxifloxacin levels, efficacy (UGT possibly induced)

• nintedanib
Aqvesme (mitapivat)

+

nintedanib

1 interaction

Caution Advised

mitapivat + nintedanib

caution advised: combo may decr. nintedanib levels, efficacy (hepatic metabolism induced)

• norethindrone (hormone replacement)
Aqvesme (mitapivat)

+

norethindrone (hormone replacement)

1 interaction

Caution Advised

mitapivat + norethindrone (hormone replacement)

caution advised: combo may decr. norethindrone levels, efficacy (hepatic metabolism induced)

• omeprazole
Aqvesme (mitapivat)

+

omeprazole

1 interaction

Caution Advised

mitapivat + omeprazole

caution advised: combo may decr. omeprazole levels, efficacy (hepatic metabolism induced)

• ondansetron
Aqvesme (mitapivat)

+

ondansetron

1 interaction

Caution Advised

mitapivat + ondansetron

caution advised: combo may decr. ondansetron levels, efficacy (hepatic metabolism induced)

• osimertinib
Aqvesme (mitapivat)

+

osimertinib

1 interaction

Caution Advised

mitapivat + osimertinib

caution advised: combo may decr. osimertinib levels, efficacy (hepatic metabolism induced)

• paclitaxel
Aqvesme (mitapivat)

+

paclitaxel

1 interaction

Caution Advised

mitapivat + paclitaxel

caution advised: combo may decr. paclitaxel levels, efficacy (hepatic metabolism induced)

• pazopanib
Aqvesme (mitapivat)

+

pazopanib

1 interaction

Caution Advised

mitapivat + pazopanib

caution advised: combo may decr. pazopanib levels, efficacy (hepatic metabolism induced)

• pibrentasvir
Aqvesme (mitapivat)

+

pibrentasvir

1 interaction

Caution Advised

mitapivat + pibrentasvir

caution advised: combo may incr. pibrentasvir levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

• pitolisant
Aqvesme (mitapivat)

+

pitolisant

1 interaction

Caution Advised

mitapivat + pitolisant

caution advised: combo may decr. pitolisant levels, efficacy (hepatic metabolism induced)

• polatuzumab vedotin
Aqvesme (mitapivat)

+

polatuzumab vedotin

1 interaction

Caution Advised

mitapivat + polatuzumab vedotin

caution advised: combo may decr. polatuzumab vedotin levels, efficacy (hepatic metabolism induced)

• prednisolone
Aqvesme (mitapivat)

+

prednisolone

1 interaction

Caution Advised

mitapivat + prednisolone

caution advised: combo may decr. prednisolone levels, efficacy (hepatic metabolism induced)

• progesterone (hormone replacement)
Aqvesme (mitapivat)

+

progesterone (hormone replacement)

1 interaction

Caution Advised

mitapivat + progesterone (hormone replacement)

caution advised: combo may decr. progesterone levels, efficacy (hepatic metabolism induced)

• progesterone vaginal (hormone replacement)
Aqvesme (mitapivat)

+

progesterone vaginal (hormone replacement)

1 interaction

Caution Advised

mitapivat + progesterone vaginal (hormone replacement)

caution advised: combo may decr. progesterone levels, efficacy (hepatic metabolism induced)

• propafenone
Aqvesme (mitapivat)

+

propafenone

1 interaction

Caution Advised

mitapivat + propafenone

caution advised: combo may decr. propafenone levels, efficacy (hepatic metabolism induced)

• quinidine (CYP2D6 inhibitor)
Aqvesme (mitapivat)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Caution Advised

mitapivat + quinidine (CYP2D6 inhibitor)

caution advised: combo may decr. quinidine levels, efficacy (hepatic metabolism induced)

• quinine
Aqvesme (mitapivat)

+

quinine

1 interaction

Caution Advised

mitapivat + quinine

caution advised: combo may decr. quinine levels, efficacy (hepatic metabolism induced)

• raltegravir
Aqvesme (mitapivat)

+

raltegravir

1 interaction

Caution Advised

mitapivat + raltegravir

caution advised: combo may decr. raltegravir levels, efficacy (UGT possibly induced)

• ramelteon
Aqvesme (mitapivat)

+

ramelteon

1 interaction

Caution Advised

mitapivat + ramelteon

caution advised: combo may decr. ramelteon levels, efficacy (hepatic metabolism induced)

• regorafenib
Aqvesme (mitapivat)

+

regorafenib

1 interaction

Caution Advised

mitapivat + regorafenib

caution advised: combo may decr. regorafenib levels, efficacy (hepatic metabolism induced)

• risperidone
Aqvesme (mitapivat)

+

risperidone

1 interaction

Caution Advised

mitapivat + risperidone

caution advised: combo may decr. risperidone levels, efficacy (hepatic metabolism induced)

• ritlecitinib
Aqvesme (mitapivat)

+

ritlecitinib

1 interaction

Caution Advised

mitapivat + ritlecitinib

caution advised: combo may decr. ritlecitinib levels, efficacy (hepatic metabolism induced)

• ruxolitinib
Aqvesme (mitapivat)

+

ruxolitinib

1 interaction

Caution Advised

mitapivat + ruxolitinib

caution advised: combo may decr. ruxolitinib levels, efficacy; may incr. active metabolite levels, risk of adverse effects (hepatic metabolism induced)

• siponimod
Aqvesme (mitapivat)

+

siponimod

1 interaction

Caution Advised

mitapivat + siponimod

if also combined w/ moderate or strong CYP2C9 inducer, caution advised; if CYP2C9*1/*3 or *2/*3 genotype, caution advised: combo may decr. siponimod levels, efficacy (hepatic metabolism induced)

• sorafenib
Aqvesme (mitapivat)

+

sorafenib

1 interaction

Caution Advised

mitapivat + sorafenib

caution advised: combo may decr. sorafenib levels, efficacy (hepatic metabolism induced)

• sunitinib
Aqvesme (mitapivat)

+

sunitinib

1 interaction

Caution Advised

mitapivat + sunitinib

caution advised: combo may decr. sunitinib levels, efficacy (hepatic metabolism induced)

• suvorexant
Aqvesme (mitapivat)

+

suvorexant

1 interaction

Caution Advised

mitapivat + suvorexant

caution advised: combo may decr. suvorexant levels, efficacy (hepatic metabolism induced)

• telisotuzumab vedotin
Aqvesme (mitapivat)

+

telisotuzumab vedotin

1 interaction

Caution Advised

mitapivat + telisotuzumab vedotin

caution advised: combo may decr. telisotuzumab vedotin levels, efficacy (hepatic metabolism induced)

• terbinafine
Aqvesme (mitapivat)

+

terbinafine

1 interaction

Caution Advised

mitapivat + terbinafine

caution advised: combo may decr. terbinafine levels, efficacy (hepatic metabolism induced)

• tivozanib
Aqvesme (mitapivat)

+

tivozanib

1 interaction

Caution Advised

mitapivat + tivozanib

caution advised: combo may decr. tivozanib levels, efficacy (hepatic metabolism induced)

• trabectedin
Aqvesme (mitapivat)

+

trabectedin

1 interaction

Caution Advised

mitapivat + trabectedin

caution advised: combo may decr. trabectedin levels, efficacy (hepatic metabolism induced)

• trazodone
Aqvesme (mitapivat)

+

trazodone

1 interaction

Caution Advised

mitapivat + trazodone

caution advised: combo may decr. trazodone levels, efficacy (hepatic metabolism induced)

• tretinoin
Aqvesme (mitapivat)

+

tretinoin

1 interaction

Caution Advised

mitapivat + tretinoin

caution advised: combo may decr. tretinoin levels, efficacy (hepatic metabolism induced)

• triamcinolone
Aqvesme (mitapivat)

+

triamcinolone

1 interaction

Caution Advised

mitapivat + triamcinolone

caution advised: combo may decr. triamcinolone levels, efficacy (hepatic metabolism induced)

• triazolam
Aqvesme (mitapivat)

+

triazolam

1 interaction

Caution Advised

mitapivat + triazolam

caution advised: combo may decr. triazolam levels, efficacy (hepatic metabolism induced)

• upadacitinib
Aqvesme (mitapivat)

+

upadacitinib

1 interaction

Caution Advised

mitapivat + upadacitinib

caution advised: combo may decr. upadacitinib levels, efficacy (hepatic metabolism induced)

• vandetanib
Aqvesme (mitapivat)

+

vandetanib

1 interaction

Caution Advised

mitapivat + vandetanib

caution advised: combo may decr. vandetanib levels, efficacy (hepatic metabolism induced)

• vincristine
Aqvesme (mitapivat)

+

vincristine

1 interaction

Caution Advised

mitapivat + vincristine

caution advised: combo may decr. vincristine levels, efficacy (hepatic metabolism induced)

• vinorelbine
Aqvesme (mitapivat)

+

vinorelbine

1 interaction

Caution Advised

mitapivat + vinorelbine

caution advised: combo may decr. vinorelbine levels, efficacy (hepatic metabolism induced)

• vorapaxar
Aqvesme (mitapivat)

+

vorapaxar

1 interaction

Caution Advised

mitapivat + vorapaxar

caution advised: combo may decr. vorapaxar levels, efficacy (hepatic metabolism induced)

• zaleplon
Aqvesme (mitapivat)

+

zaleplon

1 interaction

Caution Advised

mitapivat + zaleplon

caution advised: combo may decr. zaleplon levels, efficacy (hepatic metabolism induced)

• zolpidem
Aqvesme (mitapivat)

+

zolpidem

1 interaction

Caution Advised

mitapivat + zolpidem

caution advised: combo may decr. zolpidem levels, efficacy (hepatic metabolism induced)

• zongertinib
Aqvesme (mitapivat)

+

zongertinib

1 interaction

Caution Advised

mitapivat + zongertinib

caution advised: combo may decr. zongertinib levels, efficacy (hepatic metabolism induced)